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Inflammation is an integral part of our host defense against various pathogens, but when 
uncontrolled, can drive the pathology of numerous diseases. Many of these conditions are exacerbated 
with age, and their incidences will only increase as the general population ages and lifespans increase. A 
key mediator of inflammatory responses is caspase-1. The recognition of pathogen associated molecular 
patterns (PAMPs) and damage associated molecular patterns (DAMPs) drives the formation of 
multiprotein complexes termed inflammasomes, which recruit and activate caspase-1. Caspase-1 cleaves 
numerous downstream targets, including the proinflammatory cytokines proIL-1β and proIL-18, leading 
to their maturation and release from cells. The processing and release of these cytokines and other 
inflammatory effectors mediate inflammation and trigger immune responses.  
Inflammation plays a central role in numerous diseases and novel methods to study the initiation 
of early inflammatory events and the progression of inflammation over time would provide experimental 
value. The primary assays used to measure inflammasome activation are the proteolytic cleavage of 
procaspase-1 to caspase-1 by immunoblot or secretion of IL-1β in the serum by ELISA, both of which 
have notable limitations. Measuring active caspase-1 in vitro by immunoblot is technically challenging 
and often only detectable in the supernatant from cells stimulated directly with drugs that potently 
activate caspase-1. Measuring caspase-1 activation during inflammation in vivo requires tissue removal 
from sacrificed animals, preventing the dynamic measurement of caspase-1 in individual animals 
overtime. Furthermore, immunoblot detection of caspase-1 activation is often not sensitive enough to 
detect modest and/or transient activation of caspase-1 that can drive very consequential levels of 
inflammation in disease pathogenesis. Other common methods used to detect inflammation involve 
harvesting tissues for microscopic of qRT-PCR analyses to examine the histopathology or the presence of 
2 
 
certain inflammatory markers. These techniques also require tissue removal from sacrificed animals. 
Serum IL-1β levels measured by ELISA can be used as an indirect measurement of inflammasome 
activation. During systemic inflammation, enough IL-1β can be secreted in the bloodstream to be detected 
by ELISA, but this is often not the case, especially when inflammation is localized to specific tissues. 
Even if enough IL-1β is secreted, this assay gives no insight into where the inflammation is coming from. 
We therefore sought to develop a biosensor of caspase-1 to overcome the technical limitations associated 
with monitoring inflammasome activation in vivo. Developing biosensors that directly monitor caspase-1 
activation in real time would allow for the identification of specific tissues where inflammation is 
occurring in living animals and the ability to monitor how this inflammation changes in these animals 
over time.   
To better understand the role of caspase-1 in various disease settings, we developed a series of 
bioluminescent sensors that allow us to detect and quantify caspase-1 activation. We employed a 
circularly permuted form of luciferase in which the N- and C-terminal domains necessary for 
bioluminescence are physically separated by a linker region. Caspase-1 target sequences were cloned into 
this linker region, so that upon caspase-1 activation, these sequences are cleaved allowing the two 
domains of luciferase to come together and luminescence can be quantified. In our initial screen, we 
identified biosensors that exhibited a significant increase in bioluminescence following caspase-1 
activation. We hypothesized that caspase-1 biosensors would be activated in cells and animals in response 
to inflammatory stimuli that promote caspase-1 activation. The goal of this research is to further develop 
these caspase-1 biosensors into experimental tools that can be used to study inflammation in the context 
of numerous disease models. We will use a number of inflammatory insults and infection models to 
identify biosensors that best monitor caspase-1 activation and determine the sensitivity and utility of these 
biosensors in vitro (Aim 1) and in vivo (Aim 2). 
Specific Aim 1: Define the sensitivity and specificity of caspase-1 biosensors in vitro 
We will use human THP-1 cells, a monocyte derived macrophage cell line, human monocyte derived 
macrophages and murine bone marrow derived macrophages expressing caspase-1 biosensors and 
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quantify luminescence in response to various inflammatory stimuli that activate NLRP3, NLRC4, and 
AIM2 inflammasomes. Stimuli to be tested include TLR agonists along with drugs that induce potassium 
efflux, agents that induce lysosomal destabilization, UV exposure, synthetic dsDNA and dsRNA, and 
bacterial-derived products such as flagellins. Using validated caspase-1 biosensors, we will monitor the 
kinetics of biosensor activation in response to intracellular and extracellular bacterial infections in vitro. 
In addition to measuring bioluminescence, we will measure caspase-1 activation by immunoblot and the 
production of proinflammatory cytokines/chemokines by ELISA and CBA to confirm caspase-1 
activation in this system.   
Specific Aim 2: Determine the utility of caspase-1 biosensors in monitoring inflammation in vivo  
We will generate transgenic mice expressing caspase-1 biosensors and identify lines in which biosensors 
are expressed in all tissues. Using the following models of inflammation, we will monitor biosensor 
activation in live animals and determine if areas of bioluminescence correspond to locations of caspase-1 
activation in tissues:  
1. Staphylococcus aureus infection model – We will systemically infect mice with Staphylococcus 
aureus (or PBS control) via retro-orbital injection to induce potent inflammation in animals. 
Luminescence will be measured 0, 24, 48, 72 and 96h post-infection using the IVIS. Tissues will be 
harvested and luminescence quantified ex vivo. To determine if luminescence intensity correlates with 
bacterial burden and/or markers of inflammation, infected tissues will be homogenized and plated to 
enumerate CFU. We will also measure active caspase-1 and the expression of inflammatory cytokines 
and chemokines in tissue homogenates by western blot and CBA, respectively.  
2. Colitis model – Mice will be given 2% dextran sodium sulfate (DSS) or PBS sham ad libitum in the 
drinking water for 5-7 days to induce acute colitis in animals. We will measure luminescence in vivo 
prior to DSS and 7 days post-DSS using the IVIS. We will harvest intestinal tissues on day 7 and 
measure luminescence ex vivo. Sections that exhibit strong bioluminescence and control sections that 
do not exhibit luminescence will be harvested for histopathological assessment. We will monitor 
weight loss, colonic shortening and blood in the stool to determine disease severity.  
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3. Graft-versus-host disease model – To monitor biosensor activation in alloreactive donor cells, 
allogeneic BALB/c or control syngeneic CD45.1 C57Bl/6 mice will be injected via the tail vein with 
splenocytes and bone marrow cells from caspase-1 biosensor mice. Biosensor activation will be 
monitored using the IVIS following transfer. Day 7 post-transfer, mice will be sacrificed, and 
biosensor signal will be quantified in the spleen, intestines and lymph nodes. To determine if 
probiotics ameliorate GVHD, donor and recipient mice will be given 3 injections of 
exopolysaccharide (EPS) isolated from Bacillus subtilis on days -7, -5 and -3 prior to GVHD 
induction. GVHD severity will be measured over time in live animals and in excised tissues on day 7.  
Impact: Caspase-1 biosensors may serve as an outstanding tool to monitor inflammation in live animals, 
which would have both experimental and economic value and aid in the development of therapeutic 






























REVIEW OF THE LITERATURE 
Overview 
Tschopp and colleagues first described the existence of an inflammasome in 2002, when they 
discovered a high-molecular weight, multiprotein complex containing NALP1 (now NLRP1), Pycard 
(ASC – apoptosis-associated speck-like protein containing a CARD) and proinflammatory caspases that 
were induced under inflammatory conditions (1). Since this landmark finding, several inflammasomes 
have been discovered, each activated by specific PAMPs and host-derived molecules that are indicative of 
cellular damage. Inflammasome assembly leads to the activation of cascades that coordinate the 
appropriate inflammatory response necessary for pathogen clearance. Consequently, inflammasomes are 
integral to our immune system and host defense. 
Numerous cell types, most canonically cells of the innate immune system, express cytosolic, 
nuclear and membrane-associated pattern recognition receptors (PRRs), which are capable of sensing 
general danger signals, PAMPs and DAMPs. A subgroup of cytosolic PRRs in the Nod like receptor 
(NLR) family and AIM2 (absent in melanoma 2)-like receptor (ALR) family are capable of forming 
inflammasomes (2-6). Other PYD-containing proteins, such as Pyrin also, can also form functional 
inflammasomes in response to PAMP/DAMP recognition (2-5). Assembly of these ‘canonical’ 
inflammasomes provides a platform for the recruitment and activation of caspase-1. Caspase-1 cleaves 
numerous downstream targets, including the proinflammatory cytokines proIL-1β and proIL-18; the 
processing and release of these cytokines activate other immune cells to initiate a robust inflammatory 
response.  
In addition to ‘canonical’ inflammasomes, the ‘noncanonical’ inflammasome can form in 
response to recognition of intracellular LPS by other inflammatory caspases, human caspase-4 and -5 or 
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mouse caspase-11 (2-5, 7-10). While inflammasomes have been widely studied in cells of the myeloid 
lineage, it is becoming increasingly clear that inflammasomes function in a wide variety of cell types, 
including B cells (11, 12), T cells (13-15), neurons (16-19), astrocytes (20, 21), and microglia (20, 22-24), 
hepatocytes in the liver (25), keratinocytes in the skin (26-31), and epithelial cells in the intestine (32-39).  
Since its discovery nearly two decades ago, studies on the cell and molecular biology of 
inflammasomes and their critical role in immune responses began to unravel in parallel with the 
realization that hyperactivation of inflammasomes underlies the pathology of many inflammatory diseases 
(40). While inflammasomes evolved to recognize microbial pathogens or sterile injuries, uncontrolled 
inflammasome activation has become a liability, driving the pathogenesis of many non-communicable 
diseases, which are becoming increasingly prevalent particularly in aging populations. This chapter will 
discuss the six major inflammasomes and associated components, the identification of caspase-1 as the 
critical driver of inflammation and the downstream consequences of caspase-1 activation in cells, as well 
as the role of inflammasomes in human diseases.  
Structure of Inflammasomes 
As their name suggests, nucleotide-binding oligomerization domain (NOD), leucine-rich repeat 
(LRR)-containing protein (NLRs) are characterized by the presence of a NACHT domain as well as a 
variable number of LRRs, and are broken up into two subgroups: NLRP inflammasomes containing a 
PYD domain and NLRC inflammasomes containing a CARD (caspase recruitment domain) at the amino-
terminus (Fig. 1) (2, 3, 41). The structure of most inflammasome-forming proteins is conserved between 
human and rodents, except for NLRP1. Human NLRP1 contains a PYD domain at the N-terminus, while 
this domain is absent in rodents. NLPR1 is also unique in that it contains a Function to Find domain 
(FIIND) that is not found in any other sensor. AIM2 belongs to the PYHIN (Pyrin and HIN domain) 
family of proteins, which function as immune sensors of foreign DNA (42). AIM2 inflammasomes are 
composed of a DNA-binding HIN200 (hematopoietic interferon-inducible nuclear proteins with a 200-
amino-acid repeat) domain with an N-terminal PYD motif (3). Pyrin, or TRIM20, is a member of the 
TRIM family, containing four structural units including a B30.2/SPRY domain, a coiled-coil (CC) 
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domain, a zinc finger domain (Bbox) and a PYD motif (43). For all canonical inflammasomes, receptor 
oligomerization leads to recruitment of procaspase-1 via CARD-CARD interactions (either direct or via 
the adapter, ASC) and the proximity-induced proteolytic activation of caspase-1. An inflammasome that 
forms independent of caspase-1 has been termed ‘noncanonical’. Noncanonical inflammasome activation 
occurs in response to the recognition of components of intracellular gram-negative bacteria (LPS) by the 
CARD domain of mouse caspase-11 or the analogous human caspases 4/5 (7-10).  
 
 
Figure 1. Composition of Canonical and Noncanonical Inflammasomes. NLR family members shown include 
NLRP1, mouse Nlrp1 (Nlr1b), NLRP3 and NLRC4 all of which contain NACHT domains (blue) and LRRs (green). 
NLRP1 and NLRP3 inflammasomes further contain the adaptor ASC, consisting of a PYD (orange) and CARD 
(yellow) domains, while mouse Nlrp1 and NLRC4 are capable of directly recruiting caspase-1 via their N-terminal 
CARD, though ASC can be involved. AIM2 is comprised of a DNA binding HIN200 domain (grey) and a PYD, 
allowing it to interact with DNA and subsequently oligomerize ASC. The overall architecture of Pyrin resembles 
that of its TRIM family members, with a C-terminal SPRY/B30.2 domain (blue), followed by a coiled-coil domain 
(purple) and B-box domain (green). Unlike other TRIM proteins, Pyrin contains a PYD domain at the N-terminus, 
allowing it to interact with ASC to form an inflammasome. All canonical inflammasomes recruit and oligomerize 
caspase-1. The noncanonical inflammasome forms following the recognition of intracellular LPS by other 
inflammatory caspases, caspase-11 (mouse) or caspase-4/5 (human). Guanylate binding proteins (GBPs) (green) 
help facilitate the interaction between LPS and caspases.  
 
Nlrp1b and NLRC4 can directly recruit procaspase-1 via their CARD motifs, while NLRP3, 
AIM2, Pyrin and NLRP1 utilize the bipartite PYD-CARD adaptor protein ASC (3). ASC is involved in 
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inflammasome formation via homotypic PYD-PYD and CARD-CARD interactions, acting as an adapter 
between these sensors and procaspase-1 (Fig. 1). Oligomerization of sensors nucleates the recruitment 
and polymerization of ASC. Structural analysis revealed that ASC oligomerizes through its PYD, forming 
large helical filamentous structures (44, 45). The CARD domain remains exposed from these filaments, 
providing a platform for caspase-1 recruitment (44). ASC filaments cluster into visible specks, ~1μm in 
diameter, forming large macromolecular complexes (46). The final inflammasome complex is star 
shaped, with caspase-1 radiating from central ASC and receptor complex.  
While not all inflammasomes require ASC, ASC serves as a signal amplification mechanism for 
inflammasome activation and cytokine processing (2). ASC specks are not only the site of caspase-1 
recruitment into inflammasome complexes, but may also play a role in the dissemination of inflammation. 
Several groups have demonstrated that ASC secreted from dying cells can exists in the extracellular 
environment, and that this ASC remains active and can be taken up into naïve cells where it can nucleate 
the polymerization of more ASC molecules, activate caspase-1 and promote IL-1β processing (46-48).  
 The final piece of the inflammasome puzzle is caspase-1. Procaspase-1 exists as an inactive 
zymogen. Following sensor oligomerization and ASC speck formation, procaspase-1 monomers are 
recruited into the inflammasome complex through their CARD domain. Procaspase-1 dimerizes and 
undergoes proximity-induced autoproteolytic processing, gaining full enzymatic activity (49, 50). 
Caspase-1 cleaves numerous target proteins that mediate inflammatory responses. All canonical 
inflammasomes utilize caspase-1 to elicit their effector function, though other inflammatory caspases can 
activate inflammatory pathways through noncanonical inflammasome activation.  
Function of Inflammasomes 
NLRP1 
Prior to its discovery, it was known that various microbial agents were capable of activating 
caspase-1, but the mechanism for caspase-1 activation remained unknown. Tschopp and colleagues 
hypothesized that NLRP1 might form a complex with caspase-1 via CARD-CARD interactions, 
analogous to Apaf-1-caspase-9 apoptosome formation (1). They detected a protein complex they termed 
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‘the inflammasome’ that consisted of NLRP1, ASC and inflammatory caspases that processed IL-1β (1). 
NLRP1 is 1473 amino acids long and 165.9 kDa, making it the largest NLR-forming inflammasome (51). 
Although the NLRP1 inflammasome was the first inflammasome discovered, the physiological role of 
this inflammasome is not well understood. Studying NLRP1 has been complicated by the fact that, while 
NLRP1 is found in most mammalian species, it is extremely polymorphic and has undergone extensive 
genetic diversity within species.  
Humans encode a single NLRP1 gene, while mice encode a number of NLRP1 orthologs (Nlrp1a, 
Nlrp1b, Nlrp1c), which share structural features of human NLRP1 but lack a PYD (Fig. 1). The most 
well-studied NLRP1 inflammasome is Nlrp1b, which is activated in response to Bacillus anthracis Lethal 
Toxin (LT) in certain strains of mice, driving caspase-1 activation and pyroptosis (Fig. 2) (52, 53). LT is 
an A/B toxin consisting of a cell-binding protein, protective antigen (PA), and the zinc-metalloprotease 
lethal factor (LF) (54). PA engages host cell membranes and forms a channel, translocating LF into the 
cytosol (54). LF cleaves components of mitogen-activated protein kinase (MAPK) signaling pathway to 
inactivate immune signaling and impair host defense, which is required for virulence (54). Nlrp1 in 
rodents has evolved to sense bacterial proteases as a mechanism to counteract this strategy. However, 
unlike rodent Nlrp1, human NLRP1 is not responsive to anthrax LT (55). 
Mouse Nlrp1b has multiple polymorphic alleles, some of which confer susceptibility to LT, while 
others confer resistance; macrophages from mouse strains that carry alleles 1 or 5 are susceptible 
(BALB/c and 129S1 strains) while those that carry alleles 2, 3, or 4 are resistant (C57Bl/6) (52). 
Catalytically inactive LF mutants are unable to elicit caspase-1 activation and cell death (53, 56), 
confirming that LF proteolytic activity is essential for Nlrp1 inflammasome activation. LF protease 
directly cleaves Nlrp1 at the N-terminus, inducing inflammasome/caspase-1 activation, IL-1β release, and 
pyroptosis (57-59). This cleavage site is present in LT-susceptible rat strains but absence in resistant 
strains (57), suggesting that Nlrp1 proteolysis is required for inflammasome activation in rats.  
It remained unclear whether proteolysis of Nlrp1 was limited to certain isoforms or represented a 
general mechanism for NLRP1 activation across mammalian species (55), until work by the Vance 
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laboratory revealed that proteolytic cleavage of human and rodent NRLP1 is a general mechanism for 
NLRP1 inflammasome activation (55). In humans, cleavage at the linker between the PYD and NACHT 
domains removes the N-terminal PYD domain, which functions to maintain NLRP1 in an auto-inhibited 
state (26, 55). Vance and colleagues further demonstrated that this linker region, which spans ~240 amino 
acids (51), exhibits a strong signature of positive selection, leading the authors to conclude that NLRP1 is 
evolving rapidly to become an effective sensor for novel bacterial proteases and DAMPs (55). 
While LF cleavage of Nlrp1 is only detected in LT-susceptible strains in rats, LF cleavage of 
Nlrp1 can occur in both LT-responsive and LT-unresponsive cells in mice (58), suggesting that another 
mechanism may regulate inflammasome formation in response to LT. Consistent with this idea, mouse 
and human NLRP1 undergo auto-proteolytic cleavage within the FIIND, and this cleavage is required for 
inflammasome formation and caspase-1 activation (60-62). FIIND spontaneously cleaves itself, 
generating two polypeptides which remain non-covalently associated, and ASC is recruited to the C-
terminal CARD of processed NLRP1 (Fig. 1-2) (61). In addition to LT, small molecule inhibitors of two 
serine proteases, DPP8 and DPP9, can activate Nlrp1b, driving caspase-1 activation and pyroptosis (63). 
FIIND auto-proteolysis is required for Nlrp1b inflammasome activation induced by DPP8/9 inhibitors, 
however, unlike LT, these inhibitors do not induce N-terminal cleavage (63). This indicates that while 
FIIND cleavage is required for Nlrp1 inflammasome activation, N-terminal cleavage is not.  
Interestingly, Nlrp1b inflammasome activation in response LT and DPP8/9 inhibitors requires the 
proteasome (53, 63, 64), but proteasome inhibitors do not block activation of other inflammasome, 
suggesting a novel requirement of proteasomal degradation for activation of Nlrp1. Two groups 
concomitantly discovered that proteasomal degradation of the amino-terminal domains of Nlrp1b resulted 
in the release of the C-terminal fragment that activates caspase-1 in a process called “functional 
degradation” (Fig. 2) (65, 66). Chui et al. used a genome-wide CRISPR-Cas9 knockout screen to identify 
genes involved in Nlrp1b-induced pyroptosis and found an enrichment in genes associated with the N-end 
rule pathway in LT-treated macrophages, but not in macrophages treated with DPP8/9 inhibitors (65), 
consistent with an earlier finding that the N-end rule is required for LT-mediated caspase-1 activation and 
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cytotoxicity (67). Sandstrom et al. further demonstrated that the proteasomal degradation of Nlrp1b N-
terminus released the C-terminal FIIND-CARD fragment, which was sufficient to activate caspase-1 and 
form a functional inflammasome (Fig. 2) (66). This model explains why FIIND autoproteolysis is 
required for Nlrp1 inflammasome activation. Since the proteasome is a processive protease, Nlrp1 would 
be fully degraded in the absence of FIIND processing, but the break in the polypeptide chain prevents the 
C-terminal FIIND-CARD fragment from being degraded (68). This is also an appealing model because it 
provides a functional rationale for the C-terminally placed CARD, which would be degraded if it was 
located on the N-terminus like it is on the other NLR-inflammasome forming proteins (Fig. 1) (68).  
The CRISPR screen by Chui et al. revealed that the N-end rule did not apply to DPP8/9 inhibitor-
mediated Nlrp1 inflammasome activation (65). Mass spectrometry analysis and immunoprecipitation 
assays demonstrated that DPP9 interacts with human NLRP1 FIIND and functions to maintain NLRP1 in 
an inhibited state to prevent NLRP1 inflammasome activation (Fig. 2) (69). Because NLRP1 degradation 
drives its activation, constitutive turnover could result in unwanted inflammasome activation, and DPP8/9 
may function to prevent the accumulation of bioactive FIIND-CARD fragments that activate caspase-1 
(68). Thus, N-terminal cleavage by LT and inhibition of DPP8/9 both relieve inhibitory mechanisms that 
are meant to prevent Nlrp1 inflammasome activation. Analysis of gain-of-function mutations in NLRP1 
(discussed below) suggests that other regulatory mechanisms likely exist to maintain NLRP1 in an 






Figure 2. Mechanism of NLRP1 Inflammasome Activation. FIIND undergoes auto-processing, resulting in two 
non-covalently associated peptides. DPP8/9 maintains Nlrp1 in an autoinhibited state and inhibition of DPP8/9 as 
well as N-terminal proteolysis (e.g. by anthrax lethal toxin) relives this inhibition. Subsequent proteasomal 
degradation of the N-terminal domains of NLRP1 liberates the C-terminal CARD-containing fragment that can form 
a functional inflammasome with caspase-1. The E3 ubiquitin ligase, IpaH7.8 generated by Shigella ubiquitinates 
Nlrp1, driving its proteasomal degradation and inflammasome activation. T. gondii activates Nlrp1 via an unknown 
mechanism that is independent of N-terminal and FIIND proteolysis.  
 
Additional pathogens have been shown to activate NLRP1. Listeria monocytogenes and Shigella 
flexneri were shown to activate Nlrp1b by reducing cytosolic ATP levels and inducing metabolic stress 
(70). In the case of S. flexneri, an E3 ubiquitin ligase secreted from this bacterium, IpaH7.8, directly 
ubiquitinates Nlrp1b, driving its degradation and activation (Fig. 2) (66). Other groups have also shown 
that mouse Nlrp1b and rat Nlrp1 are activated in response to Toxoplasma gondii infection, driving IL-1β 
processing and pyroptosis (71, 72), though N-terminal and FIIND cleavage were not detected in response 
to T. gondii infection (71), meaning either Nlrp1 processing may not be required for inflammasome 
activation or, more likely, that an unidentified intermediate may drive Nlrp1 inflammasome activation in 
response to T. gondii (Fig. 2). Interestingly, macrophages expressing Nlrp1 variants that confer LT-
resistance were found to respond to T. gondii, driving caspase-1 activation and pyroptosis, whereas cells 
expressing LT-susceptible Nlrp1 variants supported parasite growth (72). Taken together, these data 
suggest that NLRP1 isoforms respond to different pathogens, potentially via different mechanisms.   
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NLRP1 plays a role in numerous human diseases, though the bona fide ligand(s) for human 
NLRP1 and the mechanism of activation are not well understood. The most significant advances in the 
field have come from the identification of gain-of-function mutations in NLRP1. A number of NLRP1 
mutations have been described in two monogenic epidermal disorders, multiple self-healing palmoplantar 
carcinoma (MSPC) and familial keratosis lichenoides chronica (FKLC) (26). MSPC patients develop 
benign proliferative epithelial skin lesions in areas of the skin lacking hair follicles (palms and soles) (26). 
Lesions spontaneously resolve ~6 months, but they display similar histologic features of squamous cell 
carcinomas and can result in malignancy (26, 51). KLC is characterized by the presence of keratotic 
lesions with lichenoid histopathological features. MSPC patients were found to have mutations in the 
PYD domain of NLRP1 (A54T, A66V, M77T), while FKLC patients had deletions in the LRR domain 
and preceding linker (F787del, R843del) (26). In vitro, cells expressing MSPC and FKLC mutations 
exhibit increased ASC speck formation, pro-IL-1β processing and secretion, and increased cell death (26). 
However, the PYD domain of human NLRP1, unlike other PYD-containing inflammasomes, does not 
nucleate ASC; the CARD-containing C-terminal domain is sufficient to oligomerize ASC and activate 
inflammasome signaling (26), as demonstrated in rodents. Zhong et al. detected increased ASC speck 
formation by simply removing the PYD domain of NLRP1, supporting the hypothesis that NLRP1-PYD 
plays a role in maintaining NLRP1 in an auto-inhibited state (26). The authors found that WT-NLRP1 
exists as a monomeric species, while MSPC, FKLC and ΔPYD NLRP1 mutants spontaneously 
oligomerize, suggesting that both the PYD and LRR domains are required to maintain NLRP1 in an auto-
inhibited form and prevent aberrant inflammasome activation (26). 
Another autoinflammatory disease associated with NLRP1 is autoinflammation with arthritis and 
dyskeratosis (AIADK) also known as NLRP1-associated autoinflammation with arthritis and dyskeratosis 
(NAIAD), characterized by fevers, dyskeratosis and arthritis (69, 73). AIADK results from mutations 
between the NACHT and LRR domains (R726W) or within the FIIND (P1214R) (69). The gain-of-
function mutation in the FIIND stands out amongst the others, which all occur within or near the 
autoinhibitory domains of NLRP1. Work by Zhong et al. revealed that P1214R disrupted NLRP1-DPP9 
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association (69), further supporting a regulatory role of DPP9 in maintaining NLRP1 inhibition in human 
cells.  
All of these auto-activating mutations in NLRP1 are linked to various skin diseases (26, 69, 73), 
suggesting a role for NLRP1 in the skin in humans. Consistent with this, human keratinocytes in 
particular express high levels of NLRP1, as well as ASC, caspase-1, IL-1β and IL-18 (26, 31). NLRP1 is 
also expressed in PBMCs and lymphoid tissue (26, 74), raising the question as to why these mutations fail 
to cause systemic inflammatory diseases, such as those seen in patients harboring mutations in NLRP3 
(68). DPP8/9 inhibition was shown to activate NLRP1 in human PBMCs, resulting in significant cell 
death and IL-1β processing, indicating that these cells are competent for NLRP1 inflammasome 
activation. It could be that NLRP1 functions to provide barrier protection, analogous to NLRC4 in the 
intestine. In support of this, while NLRP1 is the primary inflammasome functioning in human skin, 
mouse keratinocytes express very low levels of inflammasome proteins Nlrp1, Nlrp3, Aim2 and Asc (31), 
making them somewhat refractory to inflammasome activation. This could be because human skin is 
more directly exposed to exogenous DAMPs, while mice have fur that provides an extra layer of 
protection.  
NLRP3 
The most well-studied inflammasome is NLRP3. NLRP3 activation involves a two-step process. 
First, PRR recognition of microbial ligands or sterile priming initiates a signaling cascade that results in 
NF-κB activation and the upregulation of proinflammatory cytokines and NLRP3 so that the cell is 
primed to quickly respond to a second insult. A diverse panel of PAMPs and DAMPs serve as ‘signal 2’, 
including bacterial pore-forming toxins, potassium efflux, extracellular ATP, mitochondrial dysfunction, 
reactive oxygen species, calcium mobilization, particulate matter, lysosomal disruption, and pathogens, 
which results in the assembly of NLRP3 inflammasomes (75-81). Potassium efflux is thought to be a 
crucial upstream mediator of NLRP3 activation (2, 79), but the mechanism by which potassium efflux 
triggers NLRP3 activation remains unclear.  
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 Factors that regulate NLRP3 inflammasome activation have been extensively studied. In addition 
to its transcriptional regulation, NLRP3 inflammasome activation is, in part, coordinated by cell biology – 
NLRP3 and associated factors must be localized to specific cellular compartments in order for the 
inflammasome to form. Furthermore, numerous post-translational modifications are in place to regulate 
NLRP3 activity under physiological conditions and in response to NLRP3-activating stimuli. These 
inherent checkpoints are critical to ensure NLRP3 inflammasomes are turned on at the appropriate time 
and downregulated following resolution of tissue damage to prevent excessive inflammation.   
Many cellular host factors are required for NLRP3 inflammasome assembly, and the availability 
of these host factors in the cell regulates NLRP3 activity. NIMA-related kinase 7 (NEK7), a serine-
threonine kinase that modulates microtubule dynamics during mitosis, has recently been identified as a 
regulator of NLRP3 inflammasome assembly and activation (82-84). In non-mitotic cells or interphase, 
NEK7 is available and binds to the LRR of NLRP3 in response to potassium efflux and ROS, though the 
catalytic activity of NEK7 is not required for NLRP3 activation (83, 84). NEK7 instead serves as a 
scaffold for NLRP3 inflammasome activation, promoting its self-oligomerization. Bruton’s tyrosine 
kinase (BTK) also plays an essential role in NLRP3 inflammasome activation. BTK physically interacts 
with ASC and NLRP3 and functions as a platform protein for the interaction between these two proteins 
(85). The Kanneganti lab recently identified DDX3X as a component of the NLRP3 inflammasome 
complex (86). DDX3X interacts with the NACHT domain of NLRP3 and facilitates its oligomerization 
(86). DDX3X is required for the pro-survival assembly of stress granules, cytoplasmic compartments of 
proteins and RNA that form and enable cells to survive in response to various stressors (86). Upon 
investigating the cross-talk between these two pathways, the authors found that inflammasome activation 
and stress granule assembly are mutually exclusive processes that both depend on DDX3X and that both 
must compete for DDX3X availability in the cell (86). The authors proposed a model where DDX3X acts 
as a live-or-die checkpoint in stressed cells – if DDX3X assembles into stress granules, it is unavailable 
for inflammasome activation and the cell survives, whereas if DDX3X is incorporated into the NLRP3 
inflammasome, the cell undergoes pyroptosis (86).  
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Various stress conditions can drive ROS production from the mitochondria, and numerous groups 
have shown that mitochondrial ROS is a potent activator of NLRP3. Accumulation of mitochondrial 
ROS, resulting from either inhibition of complex I or III of the mitochondrial respiratory chain or 
inhibition of mitophagy, which is the cell’s mechanism for clearing damaged mitochondria, leads to 
increased NLRP3 activation and IL-1β production (75). Because ROS are short-lived and can only act as 
messengers for a short distance, NLRP3 likely resides in close vicinity to the mitochondria (75). In steady 
state, NLRP3 is found colocalized with the endoplasmic reticulum (ER), but under inflammatory 
conditions, NLRP3 relocates to the perinuclear space and colocalizes with ER and mitochondria 
structures (75). Juxtaposition between ER and mitochondria forms mitochondria-associated ER 
membranes (MAMs) (87). MAMs could be the location of NLRP3 activation and ASC recruitment (75). 
Microtubules also play a role in coordinating NLRP3 inflammasome activation in cells by facilitating the 
dynein-dependent transport of ASC on mitochondria to NLRP3 on the ER (88).  
Recent work from James Chen’s group reported that the disassembly of the trans-Golgi network 
(TGN) is the common stress event driving NLRP3 activation (Fig. 3) (89, 90). The authors used cell 
fractionation assays and fluorescent microscopy approaches to better understand the subcellular 
localization of NLRP3 and found that NLRP3 colocalizes with the TGN38, a marker of TGN, in response 
to diverse NLRP3 agonists (89). Notably, the TGN appears disassembled into vesicle-like structures, 
while cis and medial Golgi networks remain intact (89). NLRP3 colocalizes with dispersed TGN in ASC 
knockout cells, indicating this process occurs upstream of ASC recruitment to the inflammasome complex 
and caspase-1 activation (89). The authors further demonstrated that TGN disassembly exposes 
negatively charged phosphatidylinositol-4-phosphates (PtdIns4P) that interact via ionic bonding to a 
conserved polybasic KKKK motif within NLRP3 (89, 90). In this way, the dispersed TGN serves as a 
scaffold for the recruitment and oligomerization of NLRP3 and subsequent polymerization of ASC (89, 
90). ER-Golgi intermediate compartments (ERGIC) mediates trafficking and sorting of cargo between 
these two organelles, and considering both the ER and Golgi are essential for NLRP3 assembly, it is 




Figure 3. Model of NLRP3 Activation on Dispersed trans-Golgi Network. TGN disassembly in response to 
NLRP3 activators triggers exposure of PI4P microdomains that recruit NLRP3 through ionic bonding between 
negatively charged PI4P and positively charged lysine residues between the PYD and NACHT domain of NLRP3. 
 
Prior to stimulation, numerous post-translational modifications maintain NLRP3 in an inactive 
conformation. NLRP3 activity is positively regulated by a number of post-translational modifications that 
include phosphorylation and ubiquitination (Fig. 4). Phosphorylation of the Y861 residue in the LRR 
domain of NLRP3 negatively regulates its activity. In response to various signal 2 agonists, protein 
tyrosine phosphatase non-receptor 22 (PTPN22) de-phosphorylates NLRP3 at this residue, thus acting as 
a positive regulator of NLRP3 inflammasome activation (91). Phosphorylation of the PYD domain of 
NLRP3 at S5 also negatively regulates its activity, causing electrostatic repulsion of PYDs, thus 
disturbing NLRP3 assembly (92). Protein phosphatase 2A (PP2A) dephosphorylates NLRP3 at S5 during 
priming, licensing NLRP3 for activation (92). Another key priming event for NLRP3 activation is JNK1-
mediated phosphorylation of NLRP3 at position S194 (S198 in human), downstream of TLR signaling 
(93). Phosphorylation at this site promotes the deubiquitination of NLRP3 and facilitates its self-
association (93). In addition to triggering the transcriptional upregulation of NLRP3, priming licenses 
inflammasome activation by initiating the deubiquitination of NLRP3 by the deubiquitinase (DUB) 
BRCC3 (BRC36 in humans) (94, 95). Protein kinase D (PKD) signaling emanating from the Golgi is also 
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required for NLRP3 activation (96). In response to NLRP3 activators, DAG accumulates at the Golgi, 
triggering the recruitment and activation of PKD (96). PKD phosphorylates NLRP3 in the NBD at 
position S293 (S295 in human), driving the release of NLRP3 from MAMs, the recruitment of ASC and 
assembly of the inflammasome (96).  
NLRP3 activity is negatively regulated by a number of post-translational modifications (Fig. 4). 
Ubiquitination can induce the proteasomal or autophagic degradation of NLRP3. An E3 ubiquitin ligase 
in the Skp-Cullin-F-box family member, F-Box L2 (FBXL2) inhibits NLRP3 activity by inducing its 
polyubiquitination and subsequent proteasomal degradation (97). LPS priming induces the degradation of 
FBXL2, extending the lifespan of NLRP3 for inflammasome formation (97). Another E3 ubiquitin ligase, 
TRIM31, also induces the ubiquitin-mediated proteasomal degradation of NLRP3 and is thought to be a 
critical feedback suppressor of inflammasome activation, since priming induces the expression of 
TRIM31 instead of inhibiting its activity (98). Dopamine serves as an endogenous inhibitor of NLRP3 by 
activating DRD1 signaling to induce NLRP3 ubiquitination and autophagic degradation via the E3 
ubiquitin ligase, MARCH7 (99).  
 
Figure 4. Schematic of Post-Translation Modifications Regulating NLRP3 Activity. Positive regulators (blue) 
and negative regulators (red) of NLRP3 inflammasome activation via phosphorylation/dephosphorylation or 
ubiquitination/deubiquitination.  
 
 Cryopyrin-Associated Periodic Syndromes (CAPS) collectively describes a clinical continuum of 
three systemic autoinflammatory disorders, Muckle-Wells syndrome (MWS), familial cold-induced 
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autoinflammatory syndrome (FCAS) and chronic infantile neurologic cutaneous articular syndrome 
(CINCA) / neonatal onset multi-system inflammatory disease (NOMID), all of which result from 
mutations in NLRP3 and manifest as nearly continuous episodes of inflammation (100). MWS, FCAS, 
and CINCA/NOMID disorders are classified as distinct disease entities, although they share several 
overlapping symptoms, and some patients even present with clinical features that overlap with more than 
one CAPS subtype (100, 101). CINCA/NOMID is the most severe of the three (101). Patients exhibit 
nearly continuous symptoms of inflammation beginning during infancy, and later develop CNS symptoms 
including chronic aseptic meningitis, cerebral atrophy, increased intracranial pressure, seizures, and 
progressive hearing loss (101). MWS presents as episodic flares of inflammation associated with rash, 
fever, arthralgia, progressive hearing loss, with some patients developing serum amyloid A amyloidosis 
(101). Inflammation in FCAS patients is triggered by cold exposure and is characterized by fever, rash, 
headaches, and arthralgia (101). Both MWS and FCAS patients can have daily baseline fatigue and flu-
like malaise (100).  
To date, more than 200 CAPS-associated mutations have been documented (85). Most of these 
mutations are located in exon 3, which encodes NACHT/NACHT-associated domains (100, 101). These 
gain-of-function mutations lead to hyperactive NLRP3 assembly and activation that occurs in the absence 
of signal 2, resulting in increased tissue inflammation that drives various disease symptoms. CAPS 
patients respond well to IL-1 targeting therapy (Anakinra) (102-104), supporting a role for IL-1β in CAPS 
pathogenesis. Other IL-1 targeting agents used include a neutralizing IL-1β antibody canakinumab and a 
soluble decoy IL-1 receptor rilonacept.  
Recently there has been a lot of interest in targeting the NLRP3 inflammasome directly. In 
addition to CAPS, NLRP3 has been implicated in the pathogenesis of a number of diseases, including 
autoimmune diseases, metabolic disorders including type 2 diabetes and obesity, atherosclerosis, gout, 
neurodegenerative disease, lung disease, liver disease, kidney disease, and ageing (3, 6, 105). Such a drug 
would need to specifically attenuate NLRP3 activity, without affecting the other inflammasomes 
necessary for antimicrobial immunity and host defense. Coll et al. recently described the development of 
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a small molecule inhibitor of NLRP3 called MCC950 (106). MCC950 specifically inhibits the activation 
of NLRP3, caspase-1 and IL-1β maturation, while NLRP1, NLRC4 and AIM2 remain fully functional 
(106). MCC950 also inhibits NLRP3 activation in vivo, attenuating experimental autoimmune 
encephalomyelitis (EAE) severity and increasing survival in a mouse model of CAPS (106). MCC950 
directly interacts with the NLRP3 NACHT domain, proximal to the Walker B motif, and blocks the 
ability of NLRP3 to hydrolyze ATP (107), a critical step for NLRP3 inflammasome activation (108). CY-
09, another NLRP3 inhibitor, also directly binds the NACHT domain in the Walker A motif of NLRP3, 
which competes binding of ATP to inhibit NLRP3 inflammasome activation (109). CY-09 is protective in 
mouse models of CAPS and type 2 diabetes (109). More recently, the drug Tranilast was found to 
specifically inhibit NLRP3. Tranilast is an analog of tryptophan metabolite and is used as an anti-
inflammatory (110). Mechanistically, Tranilast inhibits IgE-induced histamine release from mast cells, 
but more recently it was also shown to bind the NACHT domain of NLRP3 and inhibit NLRP3-NLRP3 
interactions to prevent inflammasome oligomerization (110). This drug has strong clinical potential as an 
anti-inflammatory, since it is well tolerated by patients at doses of up to 600mg/day over the course of 
months (110). The recent report by James Chen’s group demonstrated that a polybasic region of NLRP3 
is required for its recruitment to dTGN (89). This newly identified polybasic region may be a promising 
therapeutic target. 
Another approach to regulate NLRP3 activity is to inhibit the host factors that are involved in 
NLRP3 inflammasome activation or upstream signaling events that drive NLRP3 assembly. Inhibition of 
BTK, a component of the NLRP3-inflammasome complex, can be beneficial for the treatment of acute 
inflammatory diseases. The BTK inhibitor Ibrutinib has a neuroprotective effect on brain ischemia by 
suppressing inflammasome/caspase-1 activation in infarcted areas of injured brains (85). Oridonin is the 
major active ingredient of Rabdosia rubescens, a widely used herbal medicine for the treatment of 
inflammatory diseases (111). Oridonin directly binds the NACHT domain of NLRP3 at position C279 to 
prevent NLRP3 interaction with NEK7 (111). This drug was shown to have both preventative and 
therapeutic effects in mouse models of MSU-induced peritonitis and gouty arthritis as well as diabetes 
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(111). The ketone metabolite β-hydroxybutyrate (BHB) was also found to specifically suppress NLRP3 
activation, without affecting NLRC4, AIM2 or noncanonical inflammasome responses (112). BHB 
inhibits NLRP3 inflammasome activation by preventing potassium efflux, ASC oligomerization and IL-
1β production (112). Ketone bodies serve as alternative energy sources for various tissues during periods 
of nutrient deprivation and adherence to low carbohydrate diets. During these periods, metabolic signals 
like BHB dampen innate immune responses to spare ATP. Mice fed a ketogenic diet, which elevates 
serum BHB levels, were protected in a mouse model of FCAS, suggesting that dietary or pharmacological 
approaches that elevate BHB can reduce the severity of NLRP3-dependent inflammatory diseases (112). 
A number of other NLRP3-targeting drugs have been developed in addition to those mentioned here 
(reviewed in (85)).  
NLRC4 
While NLRP3 is the most well-studied inflammasome, NLRC4 is perhaps the best understood, 
likely due to the structural biology that has helped to define the inflammasome paradigm. All components 
of the NLRC4 inflammasome pathway have been identified, including the trigger (bacterial ligands), the 
sensor (NAIP proteins), the nucleator (NLRC4), the adaptor (ASC) and the effector (caspase-1). NLRC4 
is a critical component to host defense against bacterial pathogens.  
NLRC4 was initially named Ipaf (ICE-protease activating factor), identified as a pro-apoptotic 
protein capable of activating caspase-1, until the structure revealed that it belonged to the NLR family of 
proteins (40, 113). Like other inflammasome-forming proteins, NLRC4 expression is upregulated by 
proinflammatory stimuli, however basal levels of NLRC4 are sufficient for inflammasome activation in 
various cell types (40). So unlike the NLRP3 inflammasome, which is tightly regulated by transcriptional 
mechanisms (i.e. ‘signal 1’), NLRC4 inflammasome activation is primarily regulated at the post-
transcriptional level, through ligand binding (NAIP proteins) to induce the conformational activation of 
NLRC4 and phosphorylation of S533 in the LRR domain of NRLC4.    
NLRC4 is capable of recognizing a diverse panel of bacterial ligands by utilizing different sensor 
proteins in the NLR family apoptosis inhibitory protein (NAIP) family. In mice, Naip1 and Naip2 activate 
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Nlrc4 in response to conserved T3SS rod or needle proteins, while Naip5 and Naip6 serve a similar 
function to Naip1/2, activating Nlrc4 in response to cytosolic flagellin (114, 115). In contrast to mice, 
humans encode a single genetic locus for NAIP, but the gene has several transcript variants that encode 
for unique NAIP isoforms that can activate NLRC4 in response to T3SS needle protein and cytosolic 
flagellin (116, 117). Human NAIP has the highest sequence homology with murine Naip1 (118). 
Exactly how NAIP-binding of bacterial ligands drove NLRC4 inflammasome activation remained 
unclear until 2013, when Hu and colleagues resolved the X-ray crystallography structure of monomeric 
NRLC4, demonstrating that NLRC4 resides in an autoinhibited form, with intramolecular interactions 
between the C-terminal LRR domain and the nucleotide binding domain (NBD) of NACHT resulting in 
the shape of a question mark (119). Further cryo-EM studies revealed NAIP binding initiates assembly of 
9-11 NLRC4 molecules, forming a wheel-like shape (120, 121). Following NAIP binding, the C-terminal 
LRR domain of NLRC4 opens via a ~90˚ rotation along a hinge region between the LRR and NBD, 
exposing a catalytic surface for NLRC4 oligomerization and autoactivation (121). Mutations in certain 
domains of NLRC4, such as the hinge region, can allow the protein to adopt an open conformation in the 
absence of NAIP, leading to NLRC4 autoactivation and the development of severe autoinflammatory 
diseases (discussed below) (40, 122). Once oligomerized, NLRC4 recruits procaspase-1 into the 
inflammasome complex via CARD-CARD interactions. Compared to the other NLR-forming 
inflammasomes, NLRC4 is unique in that it can directly recruit caspase-1 via its C-terminal CARD. 
While NLRC4-caspase-1 activation is well-established to occur in the absence of ASC (123), interaction 
with ASC greatly augments caspase-1 activation (124, 125).  
In addition to ligand binding by NAIPs, NLRC4 is post-translationally modified by the δ isoform 
of Protein Kinase C (PKCδ) or Leucine Rich Repeat containing Kinase-2 (LRRK2), both of which 
phosphorylate Serine 533 (S533) within the LRR domain (126, 127). NLRC4 S533A mutants fail to 
recruit caspase-1, assemble ASC and process proIL-1β (126). Naip5 is required for flagellin-induced 
caspase-1 activation but is dispensable for S533 phosphorylation, suggesting that Naip-mediated sensing 
of flagellin and Nlrc4 phosphorylation are independent processes that converge upon inflammasome 
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activation (128). Interestingly, flagellin from Helicobacter pylori was shown to induce Nlrc4 S533 
phosphorylation but not inflammasome activation (128). These data led to the conclusion that S533 
phosphorylation primes NLRC4 for activation by NAIP proteins, but phosphorylation alone is not 
sufficient to induce NLRC4 inflammasome and caspase-1 activation (128).    
While NLRC4 activity is primarily regulated at the post-translational level, the expression of 
Naip genes (118) and Prkcd, the gene encoding PKCδ (129), is regulated by IFN regulatory factor 8 
(IRF8), suggesting that IRF8 may play a role in various aspects of the NLRC4 inflammasome pathway. In 
vivo, Irf8-/- mice are more susceptible to S. typhimurium infection, exhibiting significant weight loss and 
mortality comparable to Nlrc4-/- mice (118). These data demonstrate a role for IRF8 in dictating NLRC4-
mediated innate immune response against pathogenic bacteria in vitro and in vivo (130).   
The first description of human diseases associated with NLRC4 occurred in 2014, when two 
groups described autoinflammation with recurrent Macrophage Activation Syndrome (MAS) and a 
syndrome of neonatal-onset enterocolitis and periodic fever caused by gain-of-function mutations in 
NLRC4 (131, 132). Canna et al. identified a mutation (T337S) in a highly conserved region within the 
NACHT domain of NLRC4, called helical domain 1 (HD1), that they hypothesized would interfere with 
maintaining NLRC4 in an autoinhibited state, leading to increased NLRC4 inflammasome activation and 
MAS (131). Monocytes and macrophages from MAS patients exhibited elevated cytokine secretion, cell 
death and spontaneous ASC aggregation consistent with a hyperinflammatory phenotype, and in vitro, 
increased spontaneous caspase-1 activation was detected in cells expressing T337S NLRC4 compared to 
WT (131). IL-1R antagonist (anakinra) therapy, which successfully treats patients with CAPS, 
ameliorated systemic inflammation in the patient with the T337S NLRC4 mutation, but high IL-18 levels 
and macrophage hyper-responsiveness persisted (131). Romberg et al. identified a mutation (V341A) also 
within HD1, in a 23 day old patient that died from infantile enterocolitis and autoinflammation (132). In 
vitro, V341A NLRC4 promoted spontaneous caspase-1 activation, ASC oligomerization and increased 
IL-1β and IL-18 production and cell death in LPS-primed macrophages (132). As neonatal-onset 
enterocolitis resolves by 1 year of age in survivors, the authors hypothesized that this chronic 
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inflammatory state could be exacerbated in the infant’s gut due to constant exposure to bacterial ligands, 
and as the host-microbe interaction matures, it eventually reaches homeostasis and becomes less 
inflammatory (132). Other NLRC4-related autoinflammatory diseases have been reported, resulting in 
conjunctivitis, rash and skin lesions that vary in severity and localization, pain and swelling of joints from 
a S445P mutation (133) and urticarial-like rash, as well as arthritis and fever induced by exposure to cold 
stimuli that results from a H443P mutation in NLRC4 (134). All of the mutations described thus far occur 
near the putative ADP/ATP binding site, which makes sense considering that bound ADP locks NLRC4 
in an autoinhibited conformation (119).    
AIM2 
In 2008, Tschopp and colleagues observed the existence of an inflammasome that responded to 
viral, bacterial, genomic and synthetic DNA (135). Their results demonstrated that ASC and caspase-1 
were required for IL-1β secretion in response to cytosolic DNA, but NLRP3 was dispensable, leading the 
authors to conclude that the DNA sensor formed an alternative inflammasome (135). Subsequent groups 
identified the IFN-inducible HIN-200 family member, absent in melanoma 2 (AIM2), as the cytoplasmic 
DNA-sensing inflammasome (136-139). Recognition of DNA leads to the oligomerization of AIM2, 
providing a platform for ASC recruitment and caspase-1 activation, culminating in pyroptosis (138). The 
generation of Aim2-/- mice further confirmed a role for the AIM2 in host defense against viral and 
bacterial pathogens in vivo (140-142).  
AIM2 recognizes dsDNA structures non-specifically, enabling AIM2 to form inflammasomes and 
activate caspase-1 in response to diverse DNA ligands. This is accomplished through electrostatic 
attraction between negatively charged dsDNA and positively charged HIN domain residues (143). AIM2 
binds both strands of dsDNA, across the major and minor grooves, which explains its specificity for 
dsDNA instead of ssDNA (143). Optimal AIM2 activation, as measured by IL-1β release, occurs in the 
presence of ~80bp of transfected dsDNA, a length that would be able to accommodate ~20 AIM2 HIN 
domains (143). In the absence of DNA, AIM2 resides in an auto-inhibited state, with its PYD domain 
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interacting with the HIN domains (143). Once bound, AIM2 oligomerizes along the dsDNA lattice, 
leading to ASC recruitment and inflammasome assembly (143). 
AIM2 is an important sensor to our host defense because of its ability to sense DNA, a central 
component of many pathogens. But, for AIM2 to recognize pathogen-derived DNA, the DNA must 
somehow get exposed in the cytosol. For example, bacteriolysis of intracellular bacteria, such as Listeria 
monocytogenes, in the cytoplasm releases DNA that can be sensed by AIM2, triggering inflammasome 
activation and pyroptosis (144). A critical component of cell-autonomous immunity to Gram-negative 
bacteria is the production of type I IFNs and the induction of IFN-stimulated GTPases, including 
guanylate-binding proteins (GBPs) and interferon-regulated GTPases (IRGs), which target vacuolar and 
cytosolic pathogens (145-149) and enable pathogen recognition by cytosolic sensors. The concerted role 
of GBPs and IRGs is most well-studied in response to the bacterium Francisella novicida (F. novicida), 
which is the common model for Francisella tularensis in mice. F. novicida infection is sensed by the 
cGAS-STING pathway, activating type I IFN signaling and IRF1 expression. IRF1 regulates the 
expression of GBPs, which induce bacteriolysis to promote AIM2 recognition of bacterial DNA (150, 
151). Specifically, GBP2 and GBP5 are required for F. novicida-induced AIM2 activation (150, 151). 
The interferon-inducible protein IRGB10, is also essential for F. novicida-induced AIM2 activation (149). 
It is thought that GBPs control the recruitment of IRG10 to bacteria, where IRG10 localizes to bacterial 
membranes and facilitates the release of bacterial DNA into the cytosol for recognition by AIM2 (149). 
Importantly, type I IFNs and IRF1 do not contribute to AIM2 activation in response to some DNA 
ligands, such as mouse cytomegalovirus (mCMV) or transfected dsDNA (151). 
AIM2 also plays a role in sensing viral DNA, including vaccinia virus and mCMV, as mice 
deficient in Aim2 exhibit reduced inflammatory cytokine production and attenuated IFN responses, both 
of which are critical to control of viral replication (140). While AIM2 is well-established to sense viral 
DNA (137, 140), the mechanisms of how viral DNA is exposed in the cytosol for AIM2 recognition are 
not well-defined. Notably, not all DNA viruses trigger AIM2 inflammasome activation, as many have 
evolved strategies to thwart ALR sensing. For example, herpes simplex virus 1 (HSV-1) still elicits a 
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strong IL-1β response in the absence of AIM2 (140), and recently, it was shown that HSV-1 blocks AIM2 
inflammasome activation through the tegument protein VP22. Many DNA viruses have likely evolved to 
evade AIM2 sensing, since AIM2 inflammasome activation triggers rapid pyroptosis, an unfavorable 
environment for viral replication. RNA viruses, such as influenza A (IAV), and other pathogens can also 
indirectly elicit AIM2 activation by triggering the release of endogenous DNA from infected cells, which 
serves as a ligand for AIM2 (152, 153).  
Given AIM2’s ability to recognize dsDNA in a sequence-independent manner, it is not surprising 
that endogenous DNA is also a ligand for AIM2 inflammasome activation. Drugs/stimuli that induce 
changes to the nuclear envelope or DNA damage activate the AIM2 inflammasome. HIV-protease 
inhibitors, specifically Nelfinavir, were recently shown to disrupt nuclear envelope integrity, driving 
DNA relocalization into the cytoplasm where it activates the cGAS-STING pathway and primes AIM2 
inflammasome activation, driving IL-1β release and cell death (154). HIV-infected patients on 
antiretroviral therapy (ART) often experience inflammatory sequelae and this provides a potential 
mechanism contributing to chronic inflammation in these individuals. Recently, Hu et al. showed that 
AIM2 could sense DNA in the nucleus (38). In their model, Aim2-/-, Asc-/-, and caspase-1/11-/- mice 
were resistant to subtotal body irradiation (SBI)-induced lethality and intestinal damage (38). They further 
demonstrated that AIM2 localized to the nucleus upon radiation exposure and colocalized with gamma-
H2AX, a marker for dsDNA breaks (38). The authors concluded that AIM2 might be recruited to sites of 
radiation-induced DNA damage and mediate inflammasome activation and cell death (38). Since AIM2 is 
capable of sensing DNA following disruption of the nuclear envelope, this raises the question as to how 
DNA sensors are not activated during mitosis. It could be that AIM2 is regulated by an unknown mitotic 
factor(s) analogous to NEK7 for NLRP3.  
Unlike all of the other inflammasomes described here, no gain-of-function mutations in AIM2 
have been described to date. This could be because NLRs can oligomerize independent of their ligand, 
whereas AIM2 requires dsDNA for its oligomerization (155). However, aberrant AIM2 activity has been 
linked to many human diseases. AIM2 and its ALR family member, IFI16, play a role in systemic lupus 
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erythematosus (SLE), an autoimmune disease caused by abnormal self-DNA recognition processes, 
characterized by the production of auto-antibodies against various nuclear antigens. Usually, cytosolic 
DNA is rapidly degraded by DNases and extracellular DNA is rapidly cleared. In SLE patients, impaired 
dsDNA degradation and defective clearance of apoptotic cells or neutrophil extracellular traps (NETs) 
result in the accumulation of self dsDNA, driving auto-antibody production, activation of 
proinflammatory responses and a type I IFN signature (156). IFI16 contains a PYD and two HIN binding 
domains and is capable of forming inflammasomes with ASC and caspase-1 (15). The lupus susceptible 
New Zealand Black (NZB) strain is characterized by increased expression of the IFI16 orthologue, p202. 
Unlike IFI16, p202 lacks a PYD domain and is incapable of forming an inflammasome. However, it has 
been shown to bind DNA and antagonize Aim2 activity, suggesting a role for AIM2 in this disease (157, 
158). It is thought that p202 evolved in certain strains of mice to minimize Aim2-inflammatory responses, 
but the consequence for this is an increased susceptibility to Lupus (158). While the ALR family of DNA 
sensors are well appreciated to be involved in SLE pathology, their exact functions in this disease are not 
completely understood.  
AIM2 plays a role in numerous sterile inflammatory diseases. In all cases, healthy cells engulf 
necrotic cell DNA, a DAMP triggering AIM2 inflammasome activation and pyroptosis. In patients with 
acute and chronic kidney diseases, nucleosomes and dsDNA are released during necrotic cell death, and 
these DAMPs have been shown to activate the AIM2 inflammasome (159). Aim2-/- mice exhibit reduced 
renal injury, inflammation and fibrosis in a mouse model of kidney injury induced by unilateral urethral 
obstruction, and increased AIM2 expression is detected in the tubules and infiltrating leukocytes in 
nephrectomy samples from patients with human kidney diseases (159). Cytosolic DNA triggers AIM2 
activation and IL-1β production in human keratinocytes, contributing to the pathogenesis of psoriasis 
(29). AIM2 is also upregulated in atopic dermatitis lesions, suggesting a role for AIM2 in both chronic 
and acute skin diseases (160), though the source of cytosolic DNA in psoriatic keratinocytes remains 
unknown. AIM2 may be involved in many neuronal diseases as well. AIM2 is thought to be detrimental 
during ischemic brain injury, as Aim2-/- mice have reduced injury and improved neurological scores after 
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middle cerebral artery occlusion (161). CSF isolated from patients with TBI contain increased levels of 
cell-free dsDNA compared to non-trauma patients, which triggered AIM2 activation and caspase-1 
cleavage in embryonic cortical neurons in vitro (162). However, AIM2 regulates neuronal morphology 
(18) and is protective against various pathogens such as enteroviruses (17), so its expression in the CNS, 
particularly in neurons, is quite important.  
Because of its ability to sense self-DNA, AIM2 activity must be tightly regulated to prevent auto-
inflammation. As mentioned above, the identification of p202 as a negative regulator of Aim2 activity has 
led some to suggest that this protein was evolutionary selected in certain mouse strains to prevent aberrant 
Aim2 activity (158). A recently identified isoform of IFI16, IFI16-β, also negative regulates AIM2 
activation similar to mouse p202 (163). Like p202, IFI16-β contains two DNA binding HIN domains but 
lacks a PYD, so it is unable to form an inflammasome (163). IFI16-β mRNA levels are also upregulated 
in lupus (163). Another negative regulator of AIM2 inflammasome activation is TRIM11. Ubiquitinated 
TRIM11 targets AIM2 for autophagic degradation in response to DNA stimulation (164). Certain DNA 
sequences, such as the TTAGGG repeat found in telomeric DNA, abrogate nucleic acid sensing 
pathways, and work from the Fitzgerald lab revealed that a suppressive oligodeoxynucleotide termed 
A151, a synthetic ssDNA species containing four repeats of the TTAGGG motif, was capable of binding 
AIM2 and IFI16 and inhibiting downstream inflammatory responses and cell death (165). A more 
comprehensive understanding of AIM2 regulation will be important for developing therapeutics to 
prevent AIM2-induced inflammation.  
Pyrin 
Pyrin is the newest addition to the group of inflammasome-forming proteins. Pyrin is encoded by 
the gene MEFV, and mutations in MEFV result in an autoinflammatory disease called familial 
Mediterranean fever (FMF), characterized by spontaneous episodes of fever and inflammation (166). 
Pyrin (TRIM20) is a member of the TRIM family of proteins, containing many of the structural elements 
of its family members including B-box, coiled-coil and SPRY domains, except the typical RING motif, 
which confers E3 ubiquitin ligase activity, is switched out for a PYD motif. In its native state, Pyrin is 
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thought to exist as a trimer (167). Most FMF-associated gain of function mutations are clustered in the 
B30.2/SPRY domain of Pyrin, resulting in constitutive caspase-1 activation (discussed below) (166).  
The function of Pyrin was only recently uncovered in a landmark paper by Xu et al., where they 
found that bacterial Rho-activating toxins and effector proteins trigger Pyrin inflammasome activation 
(168).  Many bacterial and viral pathogens that replicate in host cells depend on the cytoskeleton to enable 
their uptake and movement within cells, and so sensors that detect modulations in cytoskeletal dynamics 
would be advantageous for pathogen detection. Rho GTPases, which act as molecular switches to 
coordinate changes in the actin cytoskeleton and other cellular activities, are frequently targeted by 
bacterial toxins during infection (169, 170). Xu et al. found that a toxin protein secreted by Clostridium 
difficile (TcdB) triggered caspase-1 activation and ASC speck formation, independently of NLRP3, 
NLRC4, AIM2 and NOD1/2 (168). Further analysis into the mechanism revealed that TcdB and other 
bacterial toxins and effector proteins (Vibrio parahaemolyticus VopS, Histophilus somni IbpA-Fic1/2, 
lostridium difficile TcdA, Burkhoderia cenocepacia TecA and Clostridium botulinum C3) modify the 
Switch I region of RhoA, resulting in its inactivation and toxin-induced Pyrin activation (Fig. 5) (168). In 
this way, Pyrin serves as a guard protein, surveying the activity of host proteins to sense if they are 
modified by pathogens (43). Inactivation of RhoA drives Pyrin inflammasome activation via the RhoA 
effector kinases PKN1 and PKN2, which bind and phosphorylate Pyrin (171). 14-3-3 regulatory proteins 
bind phosphorylated Pyrin and, in turn, block inflammasome activation (171, 172). Less PKN and 14-3-3 
binds Pyrin in FMF-knock in mice expressing mutations in human SPRY, indicating that this domain is 
important for maintaining Pyrin in an autoinhibited state (171).  
A number of drugs are used to treat patients with FMF, including colchicine, a drug that disrupts 
microtubules. Colchicine and other microtubule polymerization inhibitors were found to inhibit Pyrin 
inflammasome activation downstream of dephosphorylation and 14-3-3 dissociation but upstream of ASC 
speck formation (172, 173). In support of a role for microtubule dynamics in Pyrin inflammasome 




Figure 5. Schematic of Pyrin Inflammasome Activation. Rho-family proteins are active when bound to GTP and 
inactive when bound to GDP. GTPase-activating proteins (GAPs) inactivate Rho proteins by facilitating GTP 
hydrolysis, while guanine nucleotide exchange factors (GEFs) activate Rho proteins by inducing GDP-GTP 
exchange. Bacterial infection leads to RhoA modification and inactivation by bacterial toxins or effectors (red), 
inhibiting PKN phosphorylation of Pyrin which triggers 14-3-3 dissociation (red arrow), leading to Pyrin-ASC-
caspase-1 activation. Microtubule dynamics plays an important role in Pyrin inflammasome assembly, as 
microtubule targeting drugs prevent Pyrin-mediated ASC aggregation.  
 
 Pyrin may play a role in regulating the activity of other inflammasomes and associated 
components. The RING domain present in most TRIM proteins possess E3 ubiquitin ligase activity, 
allowing TRIM proteins to conjugate a wide range of different polyubiquitin linkages that modify target 
proteins, for example targeting cargo for degradation (174). Pyrin lacks E3 ligase activity but can directly 
bind numerous autophagic mediators, including ULK1, Beclin and ATG16L via its B-box, coiled-coil 
and/or SPRY domains (175). Consistent with earlier reports demonstrating that the SPRY domain of 
Pyrin interacts with inflammasome components NLRP3 and caspase-1 (176, 177), Pyrin was also shown 
to degrade NLRP1, NLRP3 and procaspase-1 through autophagy, suggesting a regulatory role for Pyrin 
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(175). Disease-associated mutations in the SPRY domain of Pyrin could perturb Pyrin-mediated 
degradation of other inflammasomes, such as NLRP3, leading to excessive caspase-1 activation and 
elevated IL-1β production (175).  
FMF results from mutations within the B30.2/SPRY domain of Pyrin (most frequently M680I, 
M694V, V726A). FMF is characterized by recurrent episodes of fever, abdominal/chest pain, arthritis, 
skin rash, or more severe secondary serum amyloid A protein amyloidosis, and is treated with IL-1 
inhibitors or colchicine (178). In addition to FMF, a number of other Pyrin inflammasome disorders have 
been described. Pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND) results from a 
mutations in Pyrin (S242R, E244K), resulting in disruption of a 14-3-3 binding motif and subsequent 
Pyrin inflammasome activation (179, 180). These patients present with severe neutrophil-mediated 
dermatosis, arthralgia, myalgia, cystic acne and longer episodes of fever, compared to FMF patients 
(178). In vitro, these mutations drive spontaneous ASC speck formation, caspase-1 activation and 
inflammatory cytokine secretion (179, 180). Patients with mutations between the coiled-coil and B30.2 
domain at position 577 (T577N/A/S) exhibit a similar autoinflammatory phenotype as patients with FMF, 
presenting with recurrent fevers, serositis, amyloidosis, and signs of systemic inflammation (181, 182). 
PBMCs isolated from one these patients showed increased IL-1β/cytokine responses following LPS 
stimulation (181). The high presence of FMF mutations in multiple populations support the idea that such 
mutations provide an evolutionary benefit for people with a subclinical inflammatory phenotype, where 
increased Pyrin activity may have been protective against endemic infections throughout history (178).  
Noncanonical Inflammasome Activation and Pyroptosis 
The term pyroptosis (from the Greek root pyro, relating to fire) was coined by Cookson and 
Brennan in 2001 as a way to describe a caspase-1 dependent form of programmed cell death that was 
observed in macrophages upon Salmonella typhimurium infection (183). In contrast to apoptosis where 
unwanted cells are removed quietly, pyroptosis ‘sounds the alarm’, releasing inflammatory mediators and 
alarmins, which benefits the host by promptly recruiting immune cells and driving inflammation (183, 
184). Ten years later, Vishva Dixit’s group found that caspase-11 was required for noncanonical 
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inflammasome-induced cell death (7). They determined that it was the loss of caspase-11, not caspase-1 
that protected mice from LPS-induced lethality (7). Triggering of the noncanonical inflammasome was 
later shown to be driven by the presence of cytosolic LPS, specifically the penta- or hexa-acyl lipid A 
moiety of LPS from gram negative bacteria, as a means of protection against bacteria that escape the 
vacuole (Fig. 6) (9, 10, 185).  
Cytosolic LPS from Gram-negative bacteria is thought to directly bind caspase-11 and human 
caspase-4/5 resulting in oligomerization and activation of these caspases (8), however, recent work from 
the Broz group and others has challenged this paradigm. Outer membrane vesicles (OMVs) produced by 
Gram-negative bacteria can enter cells via endocytosis and deliver LPS into the cytosol, which explains 
how LPS from extracellular bacteria can activate the noncanonical inflammasome (186). However, the 
lipid A moiety of LPS that is required for caspase-11 activation is highly hydrophobic and embedded 
within the OMV (187). Santos et al. hypothesized that another factor was required to facilitate the 
interaction of LPS with caspase-11 (187). They found that caspase-11 bound less efficiently to LPS in the 
absence of GBPs in vitro, and GBP KO mice injected with OMVs exhibited reduced levels of 
inflammatory cytokines and chemokines and reduced endotoxemia in vivo (187). These data indicate a 
requirement for GBPs in LPS sensing and caspase-11 activation, though whether GBPs directly bind LPS 
or do so indirectly through intermediate proteins remains to be determined (187). Intriguingly, imaging 
work by Man et al. depicts GBPs and IRGs encased within a layer of LPS in E. coli, which would suggest 
that GBPs and IRGs are directly accessible to the lipid A moiety of LPS within the bacterial membrane 
(149), though it is difficult to conceive how GBPs and IRGs gain access to the inner part of Gram-
negative bacterial membranes.  
Another group recently demonstrated that LPS delivery into the cytosol requires hepatocyte-
released high mobility group box 1 (HMGB1) (188). HMGB1 produced by hepatocytes during 
endotoxemia and bacterial sepsis binds LPS, mediates its uptake into lysosomal compartments in 
macrophages and endothelial cells via the receptor for advanced glycation end-products (RAGE), and 
permeabilizes the phospholipid bilayer of lysosomes to facilitate LPS leakage into the cytosol and 
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subsequent caspase-11 activation (188). It remains to be determined if other unknown factors facilitate 
caspase-4/5/11 recognition of LPS. Structural analysis of the LPS-caspase4/5/11 noncanonical 
inflammasome are needed to better understand the inflammasome paradigm and to provide a basis for the 
identification of noncanonical inflammasome inhibitors, which would be invaluable for developing 
treatments for sepsis.  
While caspase-11 activation drives pyroptosis by itself, NLRP3 inflammasome activation is 
required for cytokine secretion. The NLRP3 inflammasome is activated downstream of LPS sensing by 
inflammatory caspases, driving caspase-1 activation and IL-1β processing (Fig. 6) (7, 10, 185, 189). 
Exactly how caspase-11 activation triggers NLRP3 activation remains unclear, although recent work from 
Ruhl et al. investigated this link and found that caspase-11 activation leads to a drop in intracellular 
potassium levels, a common danger signal for NLRP3 inflammasome activation (190). This could, in 
part, explain the mechanism of NLRP3 activation downstream of caspase-11.  
It is likely that caspases-4/5/11 are capable of recognizing molecules other than LPS. Leishmania 
species was recently found to trigger noncanonical inflammasome activation (191). The parasite 
membrane glycoconjugate lipophosphoglycan (LPG) is recognized by caspase-11 in macrophages 
infected with Leishmania (191). Purified LPG does not activate caspase-4/5/11, confirming the 
involvement of an additional molecule for LPG recognition (191).  
The mechanism of noncanonical inflammasome activation-induced cell death remained unknown, 
until 2015, when two groups concurrently identified Gasdermin D (GSDMD) as the mediator of 
pyroptosis (192, 193). Shi et al. identified GSDMD in a genome-wide CRISPR screen in BMDMs, while 
Kayagaki et al. used a forward genetic screen with mutagenized mice to link GSDMD and pyroptosis 
(192, 193). GSDMD is cleaved by inflammatory caspases (caspase-1, 4, 5 and 11), releasing its N-
terminal domain (~31kDa) that perforates the plasma membrane and mediates IL-1β release, cell swelling 
and osmotic lysis (Fig. 6) (192-195). Biophysical analysis estimates GSDMD forms pores with a 
diameter of ~10-30nm, much larger than the diameter of cleaved IL-1β, which is ~4.5nm and, therefore, 
could easily pass through GSDMD pores (194, 195). Importantly, the N-terminal fragment of GSDMD 
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specifically binds phospholipids that are present on the internal leaflet of viable mammalian cell 
membranes, so GSDMD release into the extracellular environment does not cause the death of 
neighboring cells (194). Phospholipids are also present on the outer leaflet of phagosomes (194), meaning 
that GSDMD pores may provide a mechanism for bacterial escape into the cytosol. N-terminal GSDMD 
can also bind cardiolipin, a component of bacterial membranes, and is able to directly kill both Gram-
negative and Gram-positive bacteria in vitro (194), providing another mechanism of antimicrobial host 
defense.   
 
Figure 6. Mechanism of Noncanonical Inflammasome Activation and Pyroptosis. Inflammatory caspases 4/5/11 
sense intracellular LPS, driving cleavage of GSDMD into its C and N-terminal fragments. The N-terminal of 
GSDMD oligomerizes in the plasma membrane, forming pores and triggering pyroptosis. Caspase-1 is activated in 
parallel, it processes IL-1β and the bioactive cytokine is released from GSDMD pores. Other molecules including 
IL-1α and HMGB1 are also released. The formation of GSDMD pores in the plasma membrane can lead to 
pyroptosis.          
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 Pyroptosis and IL-1β secretion are temporally associated, so it is often proposed that IL-1β is 
passively released from pyroptotic cells. However, IL-1β can be secreted from living cells, providing an 
argument against an obligatory requirement of cell lysis for IL-1β release. In addition to its role in driving 
pyroptosis, GSDMD pores serve as a conduit for the passage of IL-1β across intact lipid bilayers (Fig. 6) 
(196, 197). Experimentally preventing pyroptosis (by treating cells with an osmoprotectant like glycine) 
inhibits the release of LDH and cell death but does not block pore formation and IL-1β secretion (196). 
Pyroptosis is also not a required outcome of caspase-1 activation in specific cell types. Inflammasome 
activation in neutrophils drives IL-1β secretion without concomitant cell death (198). Similarly, 
monocytes release IL-1β in the absence of pyroptosis (199, 200). As both neutrophils and monocytes are 
recruited early to sites of infection and are potent drivers of inflammatory and anti-microbial responses, 
this intrinsic resistance to pyroptotic cell death likely allows these innate immune cells time to produce 
high quantities of IL-1β and perform their effector functions without dying in a caspase-1 dependent 
manner. Pyroptosis is an important mechanism to prevent sustained inflammatory responses, by killing 
cells that would otherwise continue to propagate inflammation. Notably, neutrophils are remarkably 
short-lived, with a half-life ~6-8h and circulating monocytes have a half-life ~1 day. Pyroptosis may be 
more important in cells that are longer-lived, like tissue-resident macrophages. There could also be an 
additional regulatory step required for the initiation of pyroptosis in these cells that have yet to be 
identified.  
Importantly, GSDMD-independent mechanisms of IL-1β secretion exist (201, 202). Elegant work 
by Kate Schroder’s group dissected the role of GSDMD on IL-1β secretion. They found that early IL-1β 
release depends on GSDMD, but this is followed by GSDMD-independent IL-1β release in non 
pyroptotic primary myeloid cells, such as neutrophils or monocytes (201). This indicates that at least two 
mechanisms for IL-1β secretion exist and that the GSDMD-independent secretory pathway may be the 
primary route for IL-1β release in certain cell types or in specific contexts (201). Notably, ectopic 
expression of mature IL-1β but not proIL-1β is slowly released from macrophages in the absence of 
inflammatory stimuli, caspase-1 or GSDMD, indicating that maturation is not only necessary but 
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sufficient for IL-1β secretion (201). Under physiological conditions (neutral pH), proIL-1β is negatively 
charged and repelled by the plasma membrane. IL-1β maturation exposes a positively charged polybasic 
motif that enables electrostatic interactions with membranes (201). Specifically, mature IL-1β is recruited 
to negatively charged phosphatidylinositol 4,5-bisphosphate (PIP2)-enriched plasma membrane domains 
(201). At the EM level, plasma membrane projections and surface ruffles can be seen decorated with PIP2 
and mature IL-1β, while proIL-1β resides in intracellular locations away from the plasma membrane 
(201). This relocalization likely supports both GSDMD-dependent and GSDMD-independent IL-1β 
release from the cell.     
Inflammatory Caspases  
Caspase-1 
Caspases belong to a family of aspartate-specific cysteine proteases that have been well 
conserved throughout evolution (3). In 1989, two groups reported the identification of a protease 
responsible for cleaving IL-1β in monocytes and leukocytes (203, 204), long before the seminal 2002 
study that led to the identification of inflammasomes. The enzyme was identified three years later as IL-
1β converting enzyme (ICE) (205), later named caspase-1. Caspase-1 is present in cells as an inactive 
zymogen. Upon stimulation by a myriad of microbial and endogenous ligands, caspase-1 is recruited into 
inflammasomes via its N-terminal CARD that interacts with the CARD domain within polymerized ASC 
or, in some cases, directly with the oligomerized inflammasome (e.g., NLRC4 or mouse Nlrp1b). 
Following recruitment into the inflammasome complex, procaspase-1 undergoes proximity-induced 
proteolytic activation. Active caspase-1 cleaves several inflammatory mediators, including proIL-1β and 
proIL-18, into their mature biologically active forms.  
For a long time, it was thought that active caspase-1 was comprised of a tetramer of two p20 and 
two p10 subunits, but recent work from Kate Schroder’s group revealed that in cells, the dominant species 
of active caspase-1 are full-length p46 and a transient p33/p10 species on inflammasome complexes (Fig. 
7) (49). Recruitment of caspase-1 monomers into inflammasomes leads to the oligomerization of caspase-
1 and autoproteolytic cleavage at the interdomain linker (IDL), yielding a fully active p33/p10 dimer 
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complex. Further autoprocessing at the CARD domain linker (CDL) results in a p20/p10 species that 
rapidly dissociates from the inflammasome and inactivates (49). Thus, the inflammasome is not merely a 
platform for caspase-1 recruitment and activation; instead, caspase-1 requires association with 
inflammasomes to retain its activity. In this way, the inflammasome-caspase-1 complex functions as a 
holoenzyme, regulating the activation and self-intrinsic inactivation of caspase-1 (49). In support of this, 
caspase-1 displays promiscuity toward many substrates only when its concentration exceeds a threshold 
of ~50-100nM (206). The inflammasome hub likely facilitates this concentration requirement for caspase-








Figure 7. Caspase-1 Structure, Activation and Inactivation. Caspase-1 structure and subunits (A) identified 
species (B) and pathway of activation and inactivation (C). 1. Caspase-1 monomers are recruited to the ASC speck, 
2. Caspase-1 dimerizes and gains some activity, 3. Caspase-1 gains full activity following autoproteolytic processing 
at the IDL, 4. Caspase-1 undergoes self-cleavage at the CDL, 5. p20/p10 dissociates from inflammasomes and loses 
activity.  
 
Boucher et al. further demonstrated that inflammasome platform size and cell type dictates 
caspase-1 activity duration. Larger ASC speck formation correlates with increased caspase-1 activation 
and more rapid protease inactivation (49). Consist with these data, when they assessed NLRC4 
inflammasome activation in Asc-/- cells, in which caspase-1 can still be activated by its direct recruitment 
via CARD-CARD interactions, they found that the dominant active species was p46 and that this species 
retained activity for a longer duration compared to active caspase-1 in Asc+/+ cells (49). This sheds light 
on a previous phenomenon that active caspase-1 (p20) could not be detected in the supernatant of Asc-/- 
cells stimulated with NLRC4 ligands, despite the detection of cell death and low levels of IL-1β 
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processing, which would otherwise suggest that caspase-1 is active (207). Together, these data indicate 
that inflammasomes dimerize caspase-1 into an active but unprocessed form in the absence of ASC, and 
this caspase-1 species can initiate pyroptosis, while the fully processed caspase-1 species is required for 
optimal cytokine cleavage (Fig. 7C) (49, 207, 208). Cell type may also dictate caspase-1 activity duration, 
as active caspase-1 p46 and p33/p10 species were detected in neutrophils up to 8h following nigericin 
stimulation, compared to the 15 minute window in macrophages (49). The finding that the inflammasome 
complex and cell type govern the kinetics of caspase-1 activation makes sense considering that the larger 
the inflammasome/ASC speck, the more caspase-1 binding sites available, which would allow more rapid 
caspase-1 activation and subsequent inactivation. Additionally, cells express different levels of caspase-1, 
meaning caspase-1 activation kinetics may be regulated by the cell-type specific caspase-1 pools 
available.  
This self-intrinsic mechanism to terminate caspase-1 activity provides a way for cells to limit 
abrogated inflammatory responses, potentially without inducing cell death. Pyroptosis is likely the 
predominant and easiest way for cells to downregulate inflammatory responses, particularly in cells like 
macrophages where robust inflammasome activation results in a strong and rapid burst in caspase-1 
activity. However, in cell types such as dendritic cells, monocytes and neutrophils, where more moderate 
or weak inflammasome activation occurs, slower kinetics of caspase-1 activation may allow for cytokine 
processing and release while also allowing the cell time to repair GSDMD pores (208).  
 The critical finding in this study is that caspase-1 is only active within the inflammasome 
complex. Most inflammasomes, namely NLRP3, localize to specific areas in the cell, meaning that 
caspase-1 substrates must come in direct contact or close proximity to inflammasomes in order to be 
cleaved by caspase-1. The proposed 15 minute window for active caspase-1 in nigericin-stimulated 
macrophages would add an additional constraint for caspase-1 target selection, as this time frame may not 
allow significant trafficking of target proteins to areas of active inflammasomes prior to rapid caspase-1 
inactivation. These data support the previous observations that while caspase-1 is quite promiscuous in its 
substrate repertoire, in cells, the caspase-1 substrate repertoire is relatively small (49, 206, 209).  
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In addition to dictating the kinetics of caspase-1 activation, the inflammasome size and cell type 
may also direct caspase-1 target proteolysis. Walsh et al. found that caspase-1 substrate cleavage was 
dependent on the concentration of caspase-1 (206). For example, caspase-1 cleaves its well establish 
target proIL-1β at a wide range of concentrations ranging from 1-100nM, while caspase-1 promiscuity 
increased at higher concentrations ~100nM (206). In contrast to robust inflammasome activation in 
nigericin-stimulated macrophages, moderate inflammasome activation or ASC-independent 
inflammasomes may result in a lower concentration of caspase-1 within the signaling hub that favors 
caspase-1 cleavage of specific proteins. In other words, caspase-1 cleavage of target substrates may 
depend on the inflammatory stimuli driving caspase-1 activation (209).  
Other Inflammatory Caspases  
 In addition to caspase-1, human caspase-4 and caspase-5 are involved in initiating inflammatory 
responses. CASP4 and CASP5 are the human orthologues of murine Casp11, but the current 
understanding of caspase-4/5 activation and the mechanisms that regulate these caspases is still limited. 
Like caspase-11, caspase-4/5 undergo autoproteolysis following recognition of cytosolic LPS, driving 
noncanonical inflammasome activation. While caspases-4/5 do not cleave proIL-1β or proIL-18 into 
bioactive cytokines, they each can cleave GSDMD to drive pyroptosis (82, 192, 193, 210), which 
subsequently triggers NLRP3/caspase-1 activation and IL-1β/IL-18 secretion. In addition to the different 
caspases in humans and mice, human GBPs differ from murine Gbps due to multiple gene amplification 
in mice, and the Irg resistance system present in mice (i.e. IRG10) is absent in humans (211, 212). 
Therefore, the mechanisms of noncanonical inflammasome activation are different in humans.  
Recently, caspase-4 was shown to be central to the inflammasome response in human 
macrophages, as CASP4 deletion protects cells from cell death in response to LPS transfection (213). 
Cytosolic LPS derived from Francisella or Bacteroides vulgantus is not sensed by caspase-11 in 
BMDMs; however, caspase-4 in hMDMs recognizes both species of LPS, albeit with lower efficiency 
than LPS from E. coli (211). LPS from these bacteria are under-acylated, composed of tetra-acylated or 
monophosphoryl penta-acylated lipid A (211), as opposed to the hexa-acylated lipid A species required 
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for caspase-11 oligomerization and activation. This suggests that human caspase-4 has evolved to sense 
more diverse LPS ligands. Ectopically expressing human caspase-4 in BMDMs renders them susceptible 
to Francisella LPS-mediated cell death, confirming that human caspase-4 has an intrinsic broader 
sensitivity to LPS species (211). Like in mice, human GBPs cooperate with caspases for LPS sensing and 
noncanonical inflammasome activation. Specifically, GBP2, and to a lesser extent GBPs 1, 3 and 4, 
promote caspase-4 recognition of F. novicida and tetra-acylated LPS in human macrophages, but GBP2 is 
not involved in caspase-4 activation in response to hexa-acylated LPS (211). F. novicida infection in 
BMDMs elicits Aim2 inflammasome activation, but AIM2 is not the primary sensor of this bacterium in 
hMDMs, likely due to the absence of IRG10 in human cells, which could impair the bacteriolysis event 
required for dsDNA exposure (211). While caspase-4 is critical for LPS sensing, caspase-5 is required for 
inflammasome responses to bacterial infections and acts syngersitically with caspase-4 to regulate 
pyroptosis and downstream IL-1β production (213).  
Caspase-8 is a well-established initiator caspase that plays a central role in apoptosis. More 
recently, caspase-8 has emerged as a critical player in inflammatory responses. Like caspase-1, caspase-8 
processes IL-1β and IL-18 into their mature form (214-220) and can be recruited into inflammasome 
complexes, although caspase-8 is less efficient at triggering cytokine maturation compared to caspase-1 
(125, 219). NLRP3/ASC inflammasomes recruit caspase-8 in the absence of caspase-1, although in 
contrast to the rapid kinetics of caspase-1 activation and substrate cleavage, caspase-8 drives late 
maturation of bioactive IL-1β (~2-4h post nigericin stimulation) and cell death (219). An inflammasome 
can also form with Naip5, NLRC4 and caspase-8, and caspase-8 recruitment into this inflammasome 
complex requires ASC (125, 221). Interestingly, caspase-8 recruitment into the NLRC4 inflammasome 
occurs in WT cells, however caspase-8 is only activated in conditions when caspase-1 or GSDMD are 
inhibited (125). GSDMD-dependent pyroptosis suppresses caspase-8 activation, but in the absence of 
GSDMD, inflammasomes can engage a delayed, alternative form of lytic cell death (222). This 
inflammasome/caspase-8/GSDMD-independent proinflammatory form of cell death is thought to be 
unique among the other cell death modalities (222). Caspase-8, therefore, functions as a backup strategy 
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to guarantee cell death when components of the pyroptotic pathway are inhibited. Caspase-8 may drive 
cell death by activating caspase-3/7 to target gasdermin-E (also known as DFNA5), which also induces 
pore formation (125, 223, 224), though DFNA5 was shown to be dispensable for cell death following 
NLRC4/caspase-8 activation in vitro (225). Regardless of the mechanism, inflammasome/caspase-8 
activation-dependent cell death may be an essential host defense strategy against pathogens that have 
evolved to inhibit canonical inflammatory components. 
Biosensors and Novel Tools to Monitor Inflammation 
Monitoring the proteolytic activation of caspase-1 has remained the gold-standard technique for 
detecting inflammatory responses, since a myriad of PAMPs and DAMPs can activate numerous 
inflammasomes, all of which culminate in the activation of caspase-1. The direct analysis of caspase-1 
cleavage by western blot requires the removal of tissues from sacrificed animals or harvesting cells at 
defined time points. This can result in limited accuracy since the analysis requires different cell 
populations or animals at each time point and prevents the dynamic measurement of 
inflammasome/caspase-1 activation over time. Other assays that allow caspase-1 activation and 
inflammatory responses to be quantified with high spatial and temporal resolution would contribute 
substantially to the study of inflammatory diseases.  
A BRET-based biosensor was developed in 2012, in which the proIL-1β protein was fused to the 
C-terminus of RLuc8 (the donor) to the N-terminus of Venus (the acceptor) (226). Energy transfer 
between the donor and acceptor occurs when proIL-1β is intact and RLuc8 and Venus are in close 
proximity (<100Å), which results in Venus emission at ~535nm (226). Caspase-1 mediated cleavage of 
proIL-1β causes the N- and C-terminals to move apart and this is accompanied by a loss in energy 
transfer that can be quantified (226). This R-proIL-1β-V sensor allows for real-time ratiometric 
quantification of processed IL-1β in macrophage cell lines and BMDMs following nigericin stimulation 
(226), a DAMP that drives robust IL-1β processing. By combining the BRET technique with live cell 
microscopy, BRET signals can also be quantified in individual single cells before and after the addition of 
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inflammasome-activating stimuli (226). This technique provides a significant improvement in the 
temporal resolution of IL-1β dynamics over standard WB and ELISA assays.    
In 2013, Veit Hornung’s group published the iGLuc biosensor, a proIL-1β-gaussia luciferase 
fusion construct in which caspase-1-mediated cleavage leads to monomerization of this protein and 
increased luciferase activity that can be quantified (227). In response to inflammasome-activating stimuli, 
iGLuc-expressing macrophages secrete the processed reporter alongside endogenous IL-1β in the 
supernatant, allowing the sensor to be monitored in the supernatant without lysing cells (227). This 
construct was indirectly applied in vivo by transferring cells expressing the reporter construct into animals 
i.p and monitoring biosensor activation following listeria infection (227). Promega published a luciferase 
substrate called z-WEHD aminoluciferin in 2017, which is cleaved in response to inflammasome-
activating stimuli (228). In this system, cells are incubated 1:1 with a lytic reagent containing a 
proteasome inhibitor and the luciferin substrate and luminescence can be quantified (228). While all of 
these probes effectively monitored inflammasome activation in vitro, they have limitations in vivo. These 
include the limitations associated with tissue autofluorescence, poor tissue penetration in the case of 
substrates or short-lived signal following biosensor release into the extracellular space. 
Recently, a non-invasive fluorescent caspase-1 probe was developed that can detect caspase-1 
activation in cells and in inflamed tissues. The Cas-1 probe was synthesized by conjugating the WEHD-G 
caspase-1 substrate to Cy5.5 and Black Hole Quencher-3 (BHQ-3), a quencher of fluorescent dyes that 
emit in the red/far-red spectrum (229). Under normal conditions, the quencher suppresses Cy5.5 
fluorescence, but following caspase-1 mediated cleavage of the WEHD-G linker, the quencher is 
separated from Cy5.5 and the fluorescent signal can be detected and quantified (229). The membrane 
permeable Cas-1 probe is added to cells prior to the addition of inflammatory stimuli, and fluorescent 
activity can be monitored over time in cells where caspase-1 is active (229). The probe could also be 
injected intravenously into mice at various time points following treatment with inflammatory stimuli, 
such as LPS or DSS, to monitor fluorescence in vivo 30 minutes to 2 hours after injection or in tissues ex 
vivo (229). The probe was also applied to study caspase-1 activation in the context of cancer models and 
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Alzheimer’s disease (229). The ability to inject a probe and non-invasively track inflammatory responses 
has significant advantages over other technologies, as it has potential clinical applications (229).   
Advances in the development of protease biosensors, including circularly permutated firefly 
luciferases led to the development of a caspase-3/7 specific bioluminescent reporter called GloSensor, 
published in 2013 (230-232). Galban et al. generated tissue-specific transgenic mice expressing the 
GloSensor apoptotic reporter to monitor apoptotic responses in vivo (230). In transgenic mice where Cre-
activity localized to the pancreas, they observed GloSensor activation in the pancreas following repeated 
administration of cerulein, an inducer of apoptotic cell death due to pancreatitis (230). The caspase3/7 
GloSensor was also used for high throughput screens to test pharmacological compounds that induce 
caspase3/7 activation (230). This biosensor has since been used by other groups to study various other 











CHAPTER THREE  
MONITORING CASPASE-1 BIOSENSOR ACTIVATION IN VITRO 
Materials and Methods 
Cell Culture  
293T and THP-1 cells were obtained from the American Type Culture Collection (ATCC). Cells 
were cultured at 37˚C in 5% CO2 in DMEM (293T cells) or RPMI (THP-1 cells / MDMs), respectively, 
supplemented with 10% Fetal Bovine Serum (FBS) (Gibco) with 100 U/mL penicillin, 100 U/mL 
streptomycin and 10 μg/mL ciprofloxacin. MDMs were additionally cultured with 50 ng/mL GM-CSF 
and M-CSF. THP-1 cells were treated with 100 ng/mL PMA for 48h for differentiation into macrophages.  
293T Transfections and Luciferase Reporter Assay 
293T cells were plated at ~70 percent confluence in DMEM. Cells were transfected with a pGLO 
sensor construct containing the indicated target sequence, along with ASC and procaspase-1 expression 
plasmids using polyethylenimine (PEI, Polysciences). 24-36h later, cells were lysed in Passive Lysis 
Buffer (Promega). Firefly luciferase substrate (Promega) was added to each well and luminescence (RLU) 
was quantified.    
Generation of Stable Cell Lines  
Caspase-1 biosensors containing the indicated caspase-1 recognition sequence were synthesized 
(IDT) and cloned into pLVX (XhoI and EcoRI). Lentiviral vectors were generated by transfecting 293T 
with equal ratio of each biosensor, psPAX2 packaging construct (from Dr. Didier Trono, NIH AIDS 
Reagent Program, Cat. #11348) and vesicular stomatitis virus glycoprotein (VSVg) using PEI. After 48h, 
supernatant was harvested, filtered through a 0.45 μM filter (Millipore) and added to cells. Cells were 
transduced by spinoculation (1,200g, 2h at 13˚C) (234). After 48h, the media was replaced with media 
containing 5 μg/mL puromycin.  
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Monocyte Derived Macrophages  
 To generate MDMs, PBMCs were isolated from healthy donors and monocytes were positively 
selected using a human CD14 positive selection kit following the manufactures protocol (STEMCELL). 
MDMs were differentiated for 7 days with GM-CSF and M-CSF (50ng/mL). After differentiation, SIV-
VSVg VLPs were added to cells overnight. The next day, cells were transduced with lentiviruses to 
express the indicated biosensor. Inflammasome activation assays were performed 3 days later.  
In vitro Inflammasome Activation Assays  
Differentiated THP-1 cells were plated in 48 well or 24 well plates and stimulated with the 
indicated stimuli. Cells were primed with 10 ng/mL LPS (from E. coli 055:B5, Sigma-Aldrich) for 4h 
followed by 5 mM ATP (Invivogen) or 6.5uM nigericin (Sigma-Aldrich) 3h. Supernatant and cells were 
harvested for luciferase assays. Alternatively, cells were transfected with 10 μg/mL LPS, 10 μg/mL 
poly(dA:dT) (Sigma-Aldrich) or 100 μg/mL poly(I:C) (Sigma-Aldrich) with lipofectamine in media 
without antibiotics. 6h later, supernatant and cells were harvested for ELISA and luciferase assays. For 
caspase-1 inhibitor experiments, THP-1 cells were treated with Z-WEHD-FMK (R&D systems) or 
DMSO control for one hour prior to LPS stimulation. For in vitro luciferase measurements, cells were 
lysed and bioluminescence was quantified as described above.  
Salmonella Infection  
 The Salmonella strain used in these experiments contained a duel fluorescence reporter system 
described previously, called pDiGc (235). Bacteria were cultured overnight then subcultured 1:33 in LB 
with arabinose for 3h. OD was measured and bacteria were spun down 10,000g for 2 minutes, washed 
twice in PBS and then resuspended in RPMI. 2.5 x 107 bacteria were added to 500,000 IQAD or GSDMD 
THP-1 cells per well in a 24 well plate (MOI = 50). Bacteria were spun down onto THP-1 cells for 5 
minutes. The Mock coverslip was fixed immediately following spinoculation. 30 minutes post-infection, 
media was replaced with media containing 100μg/mL gentamycin to kill bacteria that had not entered the 
cells. 1.5h post-infection, the media was replaced with media containing 15μg/mL gentamycin, as excess 
antibiotics could be taken up by macrophages and cause intracellular killing of the bacteria. Coverslips or 
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cells were harvested at the indicated time point and fixed for immunofluorescence or lysed for luciferase 
measurements.  
Statistical Analysis  
Statistical significance was assessed using GraphPad Prism software (GraphPad Software, Inc.). 
Student t test was employed when comparing a treatment group relative to NT. One way ANOVA was 
performed when comparing a group of data, followed by either a Turkey Post Hoc test or Dunnett’s 
Multiple Comparison test to determine significance. Data are represented as means +/- standard error of 
the mean (SEM) or standard deviation (SD). P < .05 was considered significant.  
Results 
Caspase-1 Biosensor Design  
To better understand the role of caspase-1 in various disease settings, we developed a series of 
bioluminescent sensors that readily detect caspase-1 activation. We employed a circularly permuted form 
of luciferase, in which the N and C-terminal domains necessary for bioluminescence are physically 
separated by a flexible hinge region (231). Putative caspase-1 target sequences were cloned into this 
linker region, with the expectation that upon caspase-1 activation, these sequences would be cleaved, 
allowing the two domains of luciferase to come together (Fig. 8). This results in a strong gain in 
luciferase activity, so that the degree to which caspase-1 is activated can be quantified. The biosensors 
generated contained the following caspase-1 target sequences: two cleavage sequences within proIL-1β 
(214, 236), proIL-18 (237), procaspase-7 (238-240), gasdermin-D (192), GAPDH (241), a synthetic 
caspase-1 target, FESD and the well-established consensus sequence for all caspase-1 targets, WEHD 




Figure 8. Caspase-1 Biosensor Design. Schematic of the biosensor design. The indicated caspase-1 target amino 
acid sequence (red) was cloned into the circularly permuted luciferase (promega) and subsequently cloned into a 
lentiviral backbone to express this construct in cells. Caspase-1 cleavage of its target sequence will result in a gain in 
luciferase signal, which can be quantified in cells. 
 
Screen to Identify Putative Biosensors  
We tested the ability of these biosensors to measure caspase-1 activation by transiently 
expressing each construct in 293T cells. To reconstitute an inflammasome pathway in these cells, we 
additionally co-transfected procaspase-1 and ASC (226, 227) or a GFP sham, and luminescence was 






Figure 9. Caspase-1 Biosensors are Activated in 293T Cells. 293T cells were transfected with the indicated 
biosensor or pcDNA control in the presence of human procaspase-1 or ASC expression plasmids, or GFP sham 
control. 36h post-transfection, cells were lysed and luciferase was quantified. Data are expressed as fold RLU 
relative to luciferase detected in the GFP sham.  
 
Monitoring Biosensor Activation in THP-1 cells 
 To evaluate putative caspase-1 biosensors in a more biologically relevant setting, we transduced 
the human monocytic THP-1 cell line with lentiviral vectors expressing these biosensors. THP-1 cells can 
be terminally differentiated into macrophages with PMA, giving us a relevant cell line for studying 
caspase-1. Following differentiation, cells were primed with LPS for 4h, then stimulated with the ATP or 
nigericin, a bacterial toxin derived from Streptomyces hygroscopicus that acts as a potassium ionophore. 
Both stimuli drive potassium efflux, providing signal 2 for NLRP3 inflammasome activation. We 
detected the most robust biosensor activation in our THP-1 lines expressing biosensors with either the 
IQAD or GSDMD target sequence, as well as cells expressing the first caspase-1 target sequence within 
pro-IL-1β at position D26 (Fig. 10). Surprisingly, little to no bioluminescence was detected with our 
WEHD biosensor, despite the high signal we measured in 293T cells (Fig. 9-10). The other biosensors 
produced moderate luciferase signals and may be more valuable in studying caspase-1 activation in other 
models of inflammation. For example, caspase-1 targets enzymes involved in glycolysis and was shown 
to process GAPDH in response to Salmonella infection, so the GAPDH biosensor may be relevant to 
metabolic or bacterial infection studies (241). Together, these data indicate that caspase-1 biosensors are 




Figure 10. Caspase-1 Biosensors are Activated in THP-1s. THP-1 cells were transduced with the lentiviruses to 
generate cell lines expressing biosensors with the indicated caspase-1 target sequence. Cells were differentiated for 
48h, then treated with 10ng/mL LPS for 4h followed by 5mM ATP or 6.5μM nigericin, and luciferase signal was 
quantified 3h later. NT = no treatment.  
 
Based on data from our biosensor screen in THP-1 cells, we moved forward with our two best 
biosensors, IQAD and GSDMD. To further characterize our IQAD biosensor in vitro, cells were 
transfected with LPS, poly(I:C) or poly(dA:dT) and bioluminescence was quantified 6h later. We detected 
strong biosensor signal in response to poly(I:C) and poly(dA:dT), drugs that activate NLRP3 and AIM2 
inflammasomes, respectively (135, 137, 243), while minimal signal was measured in response to 
intracellular LPS, which activates the noncanonical inflammasome (Fig. 11).  
 
Figure 11. Caspase-1 Biosensors are Activated in THP-1s in Response to NLRP3 and AIM2 Agonists. THP-1s 
expressing the IQAD or GSDMD biosensors were differentiated for 48h, then transfected with lipofectamine in the 
presence of 10μg/mL LPS, 100μg/mL poly(I:C) or 10μg/mL poly(dA:dT) and luciferase was measured 6h later. 
 
 We next wanted to determine if caspase-1 biosensors were turned on during an infection. The 
enteric pathogen, Salmonella enterica serovar Typhimurium (S. typhimurium), is a gram negative rod-
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shaped intracellular bacterium that infects both humans and animal hosts. This bacterium is capable of 
activating inflammasomes via multiple pathways. TLR4 senses bacterial LPS, a major constituent of the 
outer membrane of gram-negative bacteria such as S. typhimurium, while TLR5 can recognize 
extracellular flagellin, both of which provide signal 1 for NLRP3 priming (244). Intracellular S. 
typhimurium can also disrupt host cell metabolism, driving alterations in mitochondrial ROS and NLRP3 
activation (245, 246). The presence of cytosolic flagellins and the T3SS of S. typhimurium are capable of 
activating NLRC4 (115, 116). Both NLRP3 and NLRC4 inflammasomes are critical for host defense 
against S. typhimurium, as mice lacking both NLRs are significantly more susceptible to infection (244, 
247). To determine if the IQAD and GSDMD biosensor were activated in response to S. typhimurium 
infection, THP-1 cells expressing each biosensor were infected and biosensor activation and bacterial 
replication were measured. We used a dual fluorescence reporter system in which GFP is constitutively 
expressed while arabinose-induced DsRed is diluted as the bacteria replicate (235), enabling us to identify 
infected cells and determine if the bacteria are replicating by immunofluorescence analysis, while 
monitoring biosensor activation in parallel. Biosensor activation gradually increased from 1h post 
infection to 6h post infection, and then started to decline by 8h to 24h (data not shown). Importantly, we 
detected increased luciferase signal 6h post-infection, at a time point where the bacteria were actively 









Figure 12. Biosensors are Activated during Bacterial Infection in THP-1 Cells. Differentiated IQAD or 
GSDMD-expressing THP-1 cells were infected with Salmonella at an MOI of 50. Bacteria were spun down onto 
cells for 5 minutes. 30 minutes post-infection, the media was replaced with media containing gentamycin to kill 
extracellular bacteria. At the indicated time points, coverslips were harvested for immunofluorescence to assess 
bacterial replication or cells were lysed for luciferase reads to measure biosensor activity. Data are representative 
from one experiment, expressed as fold change in luciferase relative to the uninfected cells. NT = no treatment.   
 
Monitoring Biosensor Activation in MDMs 
 Next, we isolated monocytes from human PBMCs and differentiated these cells into macrophages 
(MDMs). Primary human macrophages express retroviral restriction factors making them difficult to 
transduce with lentiviruses. SAMHD1 is a dNTPase that regulates dNTP pools and is a potent restriction 
factor for HIV-1, limiting reverse transcription. The SIV accessory protein, lentiviral protein x (Vpx), 
targets SAMHD1 for proteasomal degradation, increasing dNTP pools and relieving reverse transcription 
(248, 249). To circumvent SAMHD1 activity, we pretreated cells with vpx-containing virus like particles 
(VLPs) and then transduced these MDMs with lentiviral vectors expressing biosensors of interest. 
Biosensor signal was measured following treatment with the indicated inflammatory stimuli. Consistent 
with THP-1 cells, we detected activation of all biosensors in response to NLRP3 and AIM2 activation 
(Fig. 13, data not shown). Together, these data reveal that caspase-1 biosensors are functioning in vitro in 





Figure 13. Caspase-1 Biosensors are Activated in MDMs. Monocytes were purified from PBMCs isolated from 
healthy donors (CD14+ selection) and differentiated into macrophages with GM-CSF and M-CSF for 7 days. Cells 
were treated with SIV-VSVg VLPs on day 8, and then transduced with lentiviral vectors to express the indicated 
biosensor on day 9. 3 days later, cells were treated with LPS and ATP or nigericin or transfected with poly(I:C) or 
poly(dA:dT) and biosensor activation was quantified. 
 
IQAD Biosensors are Activated in Response to Inflammatory and Apoptotic Stimuli 
While the IQAD recognition sequence in procaspase-7 is a well-established target of caspase-1 in 
vitro and in vivo (238-240), procaspase-7 is also activated by initiator caspases caspase-8, -9 and -10 
during apoptosis (238). To confirm the IQAD biosensor was cleaved by caspase-1, cells were treated with 
an inhibitor of caspase-1, z-WEHD-FMK, then stimulated with LPS and ATP as before. We detected a 
dose-dependent decrease in biosensor signal in the presence of increasing concentrations of the caspase-1 
inhibitor (Fig. 14A). To determine if the IQAD biosensor was activated in cells during apoptosis, THP-1 
cells were treated with staurosporine and biosensor activation was quantified. While we detected 
significant biosensor activation in cell lysates following LPS and ATP treatment, we observed minimal 
biosensor activation in lysates following staurosporine treatment (Fig. 14B). However, we did observe 
significant biosensor signal in the supernatant of staurosporine treated cells, while we did not observe a 
similar increase in the supernatant of cells treated with LPS and ATP (Fig. 14B). These data suggest that 
although the IQAD biosensor can be activated in response to inflammatory and apoptotic stimuli, the 





Figure 14. IQAD Biosensors are Activated in Cells in Response to Inflammatory Stimuli but Secreted from 
Apoptotic Cells. IQAD THP-1 cells were pre-treated with the indicated concentration of z-WEHD-FMK for one 
hour, then treated with or without LPS and ATP and bioluminescence was quantified (A). Biosensor activation 
measured in the cell lysate or supernatant from IQAD THP-1 cells stimulated with LPS and ATP as before, or with 














GENERATION OF CASPASE-1 REPORTER MICE 
Materials and Methods 
Generation of Caspase-1 Reporter Mice  
Caspase-1 biosensors containing the IQAD target sequence were synthesized (IDT) and cloned 
into the EcoRI and XhoI sites of pCAG. SalI and HindIII digested DNA containing the CAG promoter 
and intron, caspase-1 biosensor and polyA sequence was purified and microinjected into zygotes of 
C57Bl/6 mice (performed by Northwestern Transgenic and Targeted Mutagenesis Laboratory). Progeny 
were genotyped by PCR of the tail DNA and transgene-positive mice were identified. The founder line 
that exhibited ubiquitous and robust transgene expression in all tissues was expanded. For transgene 
expression quantification, mouse tissues were homogenized, RNA was isolated (NucleoSpin RNA Plus, 
Macherey-Nagel) and converted to cDNA (GoScript Reverse Transcription System, Promega). Transgene 
or mouse β-actin expression was quantified by qRT-PCR using SYBR green (Bio-Rad). Caspase-1 
biosensor mice are maintained as heterozygote. All experiments were performed according to protocols 
approved by the Institutional Animal Care and Use Committee (IACUC) at Loyola University Chicago. 
All animals were housed in pathogen-free conditions at Loyola University Chicago medical campus 
(Maywood, IL); animals used for S. aureus experiments were housed in a BSL-2 facility at Loyola 
University Chicago medical campus (Maywood, IL).  
In vitro Inflammasome Activation Assays 
 BMDMs were plated in 48 well or 24 well plates and stimulated with the indicated stimuli. The 
following drug concentrations were used: 10ng/mL LPS 4h (priming), 1μg/mL LPS 16h (overnight), 
10μg/mL LPS (transfection) 6h, 5mM ATP 3h, 6.5μM nigericin 3h, 1μg/mL Pam2CSK4 4h, 10μg/mL 
Pam3CSK4 4h, 100μg/mL curdlan 24h, 125μg/mL MSU 4h, 2μg/mL flagellin 6h, 100μg/mL poly(I:C) 
56 
 
6h, 10μg/mL poly(dA:dT) 6h. Cells were with LPS for 4h followed by ATP or nigericin for 30m-1h. 
Alternatively cells were transfected with LPS, poly(I:C) or poly(dA:dT). Luciferase was quantified as 
described above. IL-1β ELISA was performed according to the manufacturer’s instructions (RayBiotech). 
Cytometric bead array (CBA) was performed according to the manufacturer’s instructions and samples 
were analyzed on an LSRFortessa (BD Biosciences). The log2fold change was calculated for each 
treatment group and heatmaps were generated using RStudio.  
Western Blotting 
Cells were stimulated with LPS and ATP as described above. Supernatant and cells were 
harvested 3h after ATP treatment. Whole-cell lysates were prepared by lysing cells in NP-40 lysis buffer 
(100 mM Tris pH 8.0, 1% NP-40, 150 mM NaCl) containing a protease inhibitor cocktail (PIC) (Roche) 
for 30 minutes on ice. Lysates were collected, mixed with 2x Laemmli sample buffer and incubated at 
100˚C for 5 minutes. For detection of caspase-1 in the supernatant, proteins were concentrated from 500 
μL of supernatant by methanol/chloroform precipitation. Protein pellets were suspended in lysis buffer 
with protease inhibitor cocktail (PIC) and sample buffer and incubated at 100˚C for 5 minutes. For 
detection of proteins in tissues, tissues were homogenized in lysis buffer with PIC and homogenates were 
shaken on ice for 30 minutes – 1 hour. Homogenates were centrifuged at 3900 rpm for 10 minutes, lysates 
were collected and protein concentration was quantified by BCA (Pierce, Thermo Fisher). Proteins were 
mixed with 2x Laemmli sample buffer and boiled as described above. Proteins were loaded onto a 4-15% 
gradient gel (Bio-Rad) and transferred to a nitrocellulose membrane (Bio-Rad). Membranes were 
incubated with anti-caspase-1 (Adipogen) or anti-β-actin (Santa Cruz Biotechnology) followed by anti-
mouse IgG conjugated to HRP (Thermo Scientific). Antibody complexes were detected using 
SuperSignal West Fempto Chemiluminescent Substrate (Thermo Scientific) and chemiluminescence was 
measured in a FluorChem E machine (ProteinSimple).   
Lactate Dehydrogenase (LDH) Measurements 
LDH cytotoxicity assay was performed according to the manufacturer’s instructions (Pierce, 
Thermo Scientific). Briefly, supernatants were collected and centrifuged to remove cell debris. Maximum 
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LDH activity was determined in supernatant from cells incubated with 10x Lysis Buffer. Background 
LDH activity present in the serum was measured using culture media.   
IVIS Imaging 
Mice were anesthetized using 2% isofluorane/air mixture delivered by the Xenogen IVIS 
Spectrum XGl-8 Gas Anesthesia system and injected i.p or i.v with a single dose of 150 mg/kg VivoGlo 
Luciferin for in vivo bioluminescence imaging. Anesthetized mice were placed in the IVIS imaging 
chamber and imaged with the IVIS 100 Imaging System (Xenogen) 10 minutes after i.p administration of 
the luciferase substrate or immediately following i.v. administration of the substrate. Bioluminescence 
was quantified and analyzed use Living Image software.  
Statistical Analysis.  
Statistical significance was assessed using GraphPad Prism software (GraphPad Software, Inc.). 
Student t test was employed when comparing a treatment group relative to NT. One way ANOVA was 
performed when comparing a group of data, followed by either a Turkey Post Hoc test or Dunnett’s 
Multiple Comparison test to determine significance. Data are represented as means +/- standard error of 
the mean (SEM) or standard deviation (SD). P < .05 was considered significant.  
Results 
Generation of Caspase-1 IQAD Biosensor Transgenic Mice 
Transgenic mice expressing the IQAD biosensor were generated by microinjection of a transgene 
containing the biosensor under control of the chicken β-actin promoter and cytomegalovirus (CMV) early 
enhancer for ubiquitous transgene expression (250-252) (Fig. 15A). The transgene was purified and 
microinjected into zygotes of C57Bl/6 mice (Fig. 15B). Offspring were genotyped by PCR of the tail 
DNA to identify positive founders. Four founder lines were initially identified (Fig. 15C), one of which 
successfully delivered positive progeny. This line exhibited ubiquitous transgene expression in all tissues 





Figure 15. Generation of Caspase Reporter Mice. Schematic of transgene, containing the CAG promoter -- CMV 
enhancer and chicken β-actin promoter followed by a chimeric intron driving expression of the IQAD biosensor 
followed by a β-globulin poly(A) signal (A). The digested transgene was purified and microinjected into zygotes (B) 
and founder lines were identified by PCR of tail DNA (C). RNA was isolated from various tissues in transgenic and 
negative control mice, converted to cDNA and qRT-PCR was performed to identify founder lines with ubiquitous 
transgene expression in all tissues (D). Representative image of luciferase signal detected following tail vein 
injection of luciferase substrate in mouse from the founder line used in these experiments (E). 
 
We next examined biosensor activation in internal organs ex vivo, including the thymus, which is 
known to have constitutively high levels of apoptosis due to ongoing negative selection of developing T 
cells. When the thymus was excised from positive transgenic mice and bioluminescence was measured, 
we observed minimal biosensor activation in the thymus ex vivo, relative to other tissues isolated (Fig. 
16). Thus, although the IQAD biosensor is activated by apoptotic stimuli in vitro, its ability to serve as a 
biosensor of apoptosis in vivo is poor, potentially due to degradation of the biosensor in the extracellular 





Figure 16. Biosensor Signal ex vivo IQAD Mice. Representative images of biosensor signal in caspase-1 biosensor 
mice. The thymus (red square) along with all other tissues isolated from the mouse. Thymus (1), heart (2), liver (3), 
lung (4), small intestine (5), spleen (6), large intestine (7) and kidney (8).  
 
Monitoring Biosensor Activation in BMDMs 
To determine if the IQAD biosensor was functioning in these transgenic mice, bone marrow cells 
from transgenic mice were isolated and differentiated into macrophages (BMDMs). BMDMs were treated 
with a panel of inflammatory stimuli and the biosensor activation generated from proteolytic cleavage of 
caspase-1 and IL-1β secretion was measured. As expected, increased luciferase activity and IL-1β 
secretion were detected in BMDMs stimulated with LPS and ATP (Fig. 17A-B) and activated caspase-1 
was detected in the supernatant of LPS and ATP stimulated BMDMs by western blot analysis (Fig. 17C). 
We also detected robust biosensor activation in BMDMs transfected with poly(dA:dT) and poly(I:C), 
similar to THP-1 cells and MDMs (Fig. 17D). To determine if these treatments were inducing cell death, 
lactate dehydrogenase (LDH) levels were measured in the supernatant, as LDH is normally found in cells 
but is released when cell membrane integrity is compromised and is thus a measurement of cytotoxicity. 
We did detect cytotoxicity in response to some inflammatory stimuli, including poly(dA:dT), which is 
known to induce pyroptosis, and poly(I:C), while no significant cell death was detected in cells treated 
with LPS and ATP (Fig. 17E). We also performed cytokine bead array (CBA) to assess cytokine and 
chemokine secretion in parallel with biosensor activation. In addition to IL-1β, LPS-primed cells treated 
with ATP secreted a panel of inflammatory cytokines, including, IL-1α, IL-6, and TNF as well as the 
chemokines keratinocyte chemoattractant (KC) CXCL1, monocyte chemoattractant protein-1 (MCP-1), 
macrophage inflammatory proteins (MIP-1α, MIP-1β) and RANTES (CCL5) (Fig. 17F). Together these 
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Figure 17. Caspase-1 Biosensors are Activated in BMDMs. BMDMs from caspase-1 reporter mice were 
stimulated with 10ng/mL LPS for 4h followed by 5mM ATP for 30m or 1h and luciferase was measured in cells, 
and IL-1β and caspase-1 were measured in the supernatant (A-C). BMDMs were transfected with lipofectamine and 
10ng/mL poly(dA:dT) or 100ng/mL poly(I:C) and luciferase was quantified 6h later (D). LDH was measured in the 
cell supernatant of BMDMs stimulated with the indicated treatment (E). The dashed red line indicates the average 
background LDH activity detected in untreated BMDM supernatant (E). Cytokine bead array was used to quantify 
cytokine/chemokine levels in the supernatant of BMDMs treated with the indicated stimuli (F). The log2 fold change 
relative to the NT group was calculated and plotted as a heatmap, where each cytokine/chemokine is displayed on 
the x-axis (F).   
 
IQAD Biosensors are Not Activated in Response to Some Inflammatory Stimuli  
 We also tested biosensor activation in response to other TLR agonist such as Pam2CSK4 and 
Pam3CSK4, which trigger TLR2-6 or TLR2-1 heterodimers to provide signal 1. Pam2 or Pam3 with ATP 
also induced robust biosensor activation and cytokine production, similar to LPS and ATP (Fig. 18A-C). 
However, we did not detect biosensor activation in response to all stimuli tested, including monosodium 
urate crystals (MSU), curdlan, and flagellin transfection (Fig. 18A). Uric acid released from dying cells 
and can act as a DAMP to drive NLRP3 inflammasome activation (255). Gout is associated with MSU 
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deposition in joints and periarticular tissues due to high levels of uric acid in the blood (255). Increased 
uric acid concentrations have also been detected in the serum of patients with MS (256). While MSU is 
well established to drive NLRP3 and caspase-1 activation following phagocytosis of crystals, we did not 
detect biosensor activation in response to MSU alone or MSU with LPS, although we did detect increased 
production of inflammatory cytokines/chemokines by CBA suggesting that an inflammatory pathway was 
activated (Fig. 18A-C). Fungal β-glucan, a major component of the fungal cell wall, can also activate the 
NLRP3 inflammasome. The large particulate β-glucan curdlan activates NLRP3 by providing signal 1 via 
dectin-1 and signal 2 following uptake into the cytosol (257). BMDMs treated with curdlan exhibited 
little to no biosensor activation and minimal cytokine/chemokine responses relative to untreated cells 
(Fig. 18A-C). We were also unable to detect biosensor activation in BMDMs transfected with flagellin 
(Fig. 18A). Lipofectamine transfection of LPS also elicited minimal biosensor activation, though we did 
detect cytokine/chemokine production by CBA (Fig. 18A-C). Cytosolic LPS activates the noncanonical 
inflammasome which ultimately drives caspase-1 activation. The LPS used in these experiments is 
serotype 055:B5 derived from E. coli, and previous reports have demonstrated serotype-dependent 
differences in noncanonical inflammasome activation (9). TLR4-priming is not serotype dependent (9), 
which could explain why we see efficient inflammasome activation in LPS-primed cells but not in 





Figure 18. Caspase-1 Biosensors are Activated in BMDMs in Response to Some Stimuli. BMDMs were 
stimulated with the indicated stimuli and biosensor activation was measured in cell lysates (A), IL-1β levels were 
measured in the supernatant by ELISA (B) and other inflammatory cytokines/chemokines were quantified in the 





Similarly, despite consistently robust biosensor activation in THP-1 cells and human MDMs 
treated with LPS and nigericin, we detected low luminescence in LPS and nigericin treated BMDMs (Fig 
19A). We still detected IL-1β secretion by ELISA and caspase-1 activation by western blot and FLICA in 
cells stimulated with nigericin, indicating that the treatment is activating caspase-1 (Fig. 19B-D). We also 
did not detect significant cytotoxicity as measured by LDH (Fig 19E) and no biosensor signal was 
detected in the cell supernatant of LPS and nigericin stimulated cells (Fig 19F), indicating that the sensor 
is not leaking out due to pyroptosis. LPS and nigericin-treated BMDMs exhibited robust expression of 
various cytokines and chemokines by CBA, similar to ATP –treated cells (Fig. 18C). Together these data 
indicate that caspase-1 is active in BMDMs treated with LPS and nigericin, but biosensor activation did 
not occur.  
 
Figure 19. Caspase-1 Biosensors are Not Activated by Nigericin in BMDMs. BMDMs were treated with LPS 
and ATP or nigericin and luciferase was measured in cells (A), IL-1β was measured in the supernatant (B), caspase-
1 activation was measured by WB (C), caspase-1 activation was measured by quantifying FLICA-positive cells by 
immunofluorescence (D), LDH was measured in the supernatant (E), and luciferase was measured in cell lysates and 











MONITORING CASPASE-1 BIOSENSOR ACTIVAITON IN VIVO 
Materials and Methods 
S. aureus Culture and Murine Systemic Infection Model 
Caspase-1 biosensor mice were infected with 107 CFU S. aureus as described previously (258-
260). Briefly, S. aureus (USA300 strain LAC) cultures were grown in tryptic soy broth (TSB) overnight 
at 37˚C and subcultured 1:100 in fresh TSB at 37˚C for 3 hours. Cultures were centrifuged, bacterial 
pellets were washed in PBS and normalized to an inoculum of 108 CFU/mL. Mice were anesthetized via 
intraperitoneal injection with 250 mg/kg Avertin and infected via the retro-orbital plexus with 100 μL 
PBS containing 107 CFU S. aureus. Tissues were isolated from infected animals and homogenized using 
an electric homogenizer. CFU were enumerated by plating tissue homogenates on tryptic soy agar (TSA) 
plates for 16 hours at 37˚C. Tissue homogenates were centrifuged at 3900rpm for 10 minutes and 
supernatant was collected for CBA analysis using BD CBA Flex sets and mouse inflammation kit (BD 
Biosciences). 
DSS-Induced Colitis Model 
Caspase-1 biosensor mice were exposed to DSS as described previously (261). Briefly, mice were 
given molecular grade water with or without 2% DSS (40,000 kDa; MP Biomedicals) for five days. For 
female mice, DSS treatment was extended 48 hours and DSS concentration was doubled to 4% for the 
final 24 hours. Mice were weighed daily throughout the course of the experiment. On day 5 or day 7, 
mice were injected with luciferase substrate and imaged in vivo. Blood samples were collected and mice 
were sacrificed. Colons and brains were excised and bioluminescence was measured ex vivo. Colon length 
was measured and fecal samples were assessed for blood using a hemoccult test (Beckman Coulter). 
Tissue sections were fixed in 10% phosphate buffered formalin, paraffin embedded, processed and 
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stained with H&E by AML laboratories (Saint Augustine, Florida) or homogenized and used for western 
blot analysis of caspase-1 activation. Colon samples were weighed and homogenized and 5μL of 
homogenates were used for CBA (BD Biosciences).    
Graft-Versus-Host Disease Model 
On day 0, WT BALB/c mice were irradiated. Caspase-1 biosensor mice were sacrificed and bone 
marrow cells were harvested as described above. For splenocyte isolation, spleens were pressed through a 
sterile 100 μm cell strainer. The cell strainer was flushed with media to dislodge the cells. Cells were 
centrifuged for 5 minutes and pellets were resuspended in ACK lysis buffer (Gibco) and washed with 
medium. Splenocytes and bone marrow cells were counted and resuspended in 300 μL PBS. T cells were 
purified (≥ 90% purity, confirmed by flow cytometric analysis of CD3 expression on purified 
splenocytes) from total splenocytes by negative selection, using biotin anti-mouse B220 [RA3-6B2], 
biotin anti-mouse CD11b [M1/70] and biotin anti-mouse CD11c [N418], followed by incubation with 
magnetic nanoparticles conjugated to streptavidin (BD IMag Streptavidin Particles Plus, BD 
Biosciences). Heparin was added prior to intravenous injection. Bone marrow cells (107) +/- 5 x 106 
splenocytes or bone marrow cells + 1.3-1.5 x 106 T cells were injected into recipient mice. All donor and 
recipients were sex matched. Serum was collected from mice on day 7 and cytokine levels were assessed 
by CBA (BD Biosciences). Clinical scores were obtained by 3 independent researchers. Mice were given 
a score of 0-2 (2 being most severe) in each of the following categories: activity, posture, fur 
texture/grooming. Scores were totaled for each mouse. Weight loss was measured separately and was not 
included in the clinical score. Percentage of donor CD8+ and CD4+ T cells and their activation status was 
analyzed by flow cytometry. All antibodies were obtained from Biolegend (anti-H-2Kd [SF11.1], anti-
CD45.1 [A20], anti-CD4 [GK1.5], anti-CD8a [53-6.7], anti-CD44 [IM7], anti-CD25 [PC61], anti-CD69 
[H1.23F]).  
Statistical Analysis 
Statistical significance was assessed using GraphPad Prism software (GraphPad Software, Inc.). 
Student t test was employed when comparing a treatment group relative to NT. One way ANOVA was 
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performed when comparing a group of data, followed by either a Turkey Post Hoc test or Dunnett’s 
Multiple Comparison test to determine significance. Data are represented as means +/- standard error of 
the mean (SEM) or standard deviation (SD). P < .05 was considered significant.  
Results 
Staphylococcus Aureus Bacterial Infection Model  
To determine if caspase-1 biosensors could be used to monitor inflammatory responses in vivo, 
we chose Staphylococcus aureus (S. aureus) skin and systemic infection models. This gram positive 
bacterium is typically found as a commensal but can become pathogenic, causing local skin infections or 
more serious systemic illness, accompanied by bacteremia, abscess formation in tissues, endocarditis, 
osteomyelitis, and morbidity and mortality (262). The bacterium encodes a number of virulence factors 
that potently stimulate inflammatory responses (263, 264). S. aureus infection triggers PRRs and 
subsequent production of inflammatory cytokines and chemokines, leading to the recruitment of 
neutrophils and abscess formation in tissues (265). Specifically, many components of the bacterial wall 
and pore-forming toxins are capable of providing signal 1 via TLR2 activation and signal 2, driving 
inflammasome activation (263, 265, 266). Multiple inflammasomes are known to be triggered by S. 
aureus, mainly NLRP3 (266-270) and caspase-1 activation is critical, as caspase-1 deficient macrophages 
are impaired in cytokine production (271).  
To test the caspase-1 biosensors in vivo, we first used a model of S. aureus skin infection. 
Biosensor mice were shaved to remove hair and intradermally infected with WT S. aureus or PBS control 
in the presence of dextran-based microcarrier beads (cytodex-3), which cause agitation to exacerbate S. 
aureus infection in the skin. Immediately after infection, 24h, 48, and 72h post-infection, mice were 
injected with 150mg/kg VivoGlo Luciferin, a luciferase substrate designed for measuring luciferase in 
live animal studies, and subjected to IVIS imaging to quantify biosensor activation at the site of infection. 
We found a significant increase in bioluminescence in infected and control animals that peaked 24h after 
infection (Fig. 20). One of the PBS control injected animals (mouse A) had a large, red bump at the 
injection site, and significant biosensor activation (Fig. 20), suggesting that the dextran-based 
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microcarrier beads used for agitation also caused inflammation and biosensor activation in these mice. 
Even though we were unable to measure biosensor signal specifically resulting from S. aureus skin 
infection, we were able to measure the onset and resolution of biosensor signal in the skin with this 
model.  
 
Figure 20. Subcutaneous S. aureus Infection and Cytodex-3 Beads Cause Biosensor Activation in the Skin. 
Representative images of caspase-1 biosensor mice inoculated with S. aureus or PBS with cytodex-3 microbeads, 
immediately after and 24h after infection (left) and image taken of mouse A 24h after inoculation with PBS with 
cytodex beads (right).  
 
We next chose to monitor S. aureus infection in the bloodstream, which induces systemic 
inflammation in mice. Caspase-1 biosensor mice were infected with S. aureus (or PBS control) via retro-
orbital injection and luminescence was quantified 0, 1, 2 and 3 days post-infection using an IVIS imaging 
system (Fig. 21A). For imaging, mice were injected i.p. with 150mg/kg VivoGlo Luciferin, a luciferase 
substrate designed for measuring luciferase in live animal studies. Biosensor signal measured in animals 
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on day 0 was set as background, and we quantified the change in this biosensor signal over the course of 
disease in PBS and infected animals. Bioluminescence accumulated in infected animals but not PBS 
controls over the course of the experiment (Fig. 21A). On day 3, infected and control mice were 
sacrificed following in vivo imaging, and the bioluminescence of individual organs was asses ex vivo. We 
detected increased luciferase signal in the livers, kidneys and hearts isolated from S. aureus-infected mice 




Figure 21. Caspase-1 Biosensors are Activated in S. aureus–Infected Mice. Representative IVIS images of 
caspase-1 biosensor mice infected with S. aureus or PBS day 0, 1, 2, and 3 post-infection (A). Regions of interest 
(ROI) (red gates) were drawn, and max radiance (p/s/cm2/sr) was quantified within each ROI. Data are expressed as 
fold max radiance relative to the max radiance detected in individual animals on day 0 (A). IVIS images of control 




Biosensor signal was quantified in tissues and bacterial CFU and cytokine expression were also 
measured to determine if bacterial burden and/or inflammatory markers coincided with areas of 
bioluminescence. We detected bacterial colonization in all kidneys and livers and some hearts isolated 
from infected mice, consistent with the increased biosensor activation detected in these tissues (Fig. 22A-
B). We also found increased expression of a panel of inflammatory cytokines and chemokines in tissues 
isolated from infected mice, relative to uninfected controls (Fig. 22C-D). These data demonstrate that 
caspase-1 biosensors are activated in vivo in response to S. aureus infection, and that we can monitor 







Figure 22. Biosensor Signal, Bacterial Burden and Inflammatory Cytokines and Chemokines Detected in 
Tissues Isolated from S. aureus-Infected Mice. Biosensor activation measured ex vivo in the kidneys and livers of 
control and infected mice (A). Tissues were homogenized in PBS and homogenates were plated on TSA plates to 
enumerate bacterial CFU (B). Homogenates were centrifuged and supernatant was collected for CBA analysis 
(C and D). ND = not detectable.  
 
Lastly, we wanted to determine if there was a correlation between biosensor signal, bacterial 
burden and IL-1β in tissues. The tissue specific role of inflammation and bacterial persistence or 
clearance is not well defined. Inflammation seems to be important in the skin, driving bacterial clearance 
(265, 266). In systemic infections, inflammation may be more harmful for the host causing sepsis, though 
there is conflicting evidence as to whether inflammation drives bacterial clearance or persistence in 
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different tissues (263, 266, 272). We detected the strongest inflammatory response and bacterial 
colonization in the kidneys, and we measured a positive correlation between CFU and IL-1β as well as 
CFU and the biosensor signal (Fig. 23). There was also a trending correlation between the biosensor 
signal and the presence of various inflammatory cytokines and chemokines including IL-1, TNF, KC and 
MIP1 (Fig. 24). However this was not the case in the liver and heart where there was little to no 
correlation between CFU, biosensor signal, and inflammatory markers (Fig 25). Profiling inflammatory 
responses ex vivo come with the caveat that these are static measurements of a dynamic process. Caspase-
1 may be activated earlier during disease, prior to the appearance of inflammatory cytokines/chemokines 
in tissues. A greater sample size may be required in order to determine the tissue-specific role of 
inflammation on bacterial survival or clearance.  
 
Figure 23. Biosensor Signal and IL-1β Correlate with Bacterial CFU in the Kidneys. Correlation graphs of 
biosensor signal (p/s/cm2/sr) or IL-1β plotted against bacterial CFU in the kidneys from control (3) and S. aureus-




Figure 24. Biosensor Signal Correlates with Inflammatory Markers in the Kidneys. Correlation graphs of 





Figure 25. Biosensor Signal and IL-1β do not Correlate with Bacterial CFU in the Liver and Heart. 
Correlation graphs of biosensor signal (p/s/cm2/sr) or IL-1β plotted against bacterial CFU in the liver (top) or heart 
(bottom) from control (3) and S. aureus-infected (8) mice.   
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DSS-Induced Colitis Model 
To measure biosensor activation during intestinal inflammation, we used an established model of 
dextran sodium sulfate (DSS)-induced ulcerative colitis (UC) (261). We chose this model because, in the 
absence of caspase-1, DSS-induced colitis is ameliorated, indicating caspase-1 activation is essential for 
intestinal inflammation (273-275). Mice were treated with 2% DSS ad libitum in the drinking water for 5 
or 7 days to induce acute colitis. On day 5 or day 7, following administration of the luciferase substrate, 
biosensor signal was measured in vivo and then mice were sacrificed and colons extracted for ex vivo 
analyses. Unfortunately, we were unable to detect bioluminescence in the colons of most mice with mild 
to moderate colitis in vivo (Fig. 26A), likely because the colon is embedded behind the small intestines in 
these animals and monitoring small changes in biosensor signal in the abdomen of these mice is difficult 
due to the strong background signal in that area. However, in some mice with more severe colitis, we 
were able to detect increased bioluminescence in the abdomen (Fig. 26B).  
 
Figure 26. Biosensor Signal in the Colons in vivo. Biosensor activation (p/s/cm2/sr) in 1 control and 3 DSS-treated 
mice, 5 days after exposure to 2% DSS (A). Mice were injected with luciferase substrate via the tail vein and 
biosensor activation was measured immediately (A). Biosensor activation (p/s/cm2/sr) in 1 control and 2 DSS-
treated mice, 7 days after exposure to 2% DSS (B). Mice were injected i.p with luciferase substrate and biosensor 
activation was measured after 10 minutes (B). Bodyweight loss (%) is shown for each animal.  
Ex vivo, the colon was measured, as colonic shortening correlates with acute inflammation 
severity. We also monitored for blood in the stool using a Hemoccult test. In this model, mice treated with 
75 
 
2% DSS for 5 days exhibit mild symptoms of colitis – little to no weight loss, slight colonic shortening, 
and blood in the stool of some but not all mice (Fig. 27A-C). By day 7, we detect increased weight loss in 
the DSS-treated mice, and most mice exhibit colonic shortening and positive Hemoccult tests (Fig. 27C, 
data not shown).  
 
Figure 27. Mice Exhibit Some Clinical Measurements of Colitis on Day 5 and Day 7. Representative Hemoccult 
images and results (+ = positive test, - = negative test) in control and DSS mice (A). Representative experiment with 
weight loss, colon length and Hemoccult test results in in control and DSS mice 5 days after DSS exposure (B). 
Weight loss in mice on day 5 versus day 7 in control and DSS mice (C).    
 
We detected biosensor activation in colons isolated from DSS-treated mice on day 5 in males and 
day 7 in males and females (Fig. 28-29). Biosensor activation appeared segmented throughout the colon 
in most mice or localized to the distal region. Areas where we detected biosensor activation and control 
regions that did not exhibit bioluminescence were sectioned and stained with H&E for histopathological 
assessment or were isolated for western blot analysis of active caspase-1. In tissue sections derived from 
areas of biosensor activation, we found nodules with inflammatory infiltrate in the mucosa and 
submucosa regions of the colon, as well as a loss of crypt integrity, reduction of goblet cells, disruption of 
the epithelial barrier, neutrophil infiltration, edema and thickening of the muscularis mucosae in H&E 
sections (Fig. 28-29). None of these inflammatory hallmarks were found in control sections from the 
same mice, although we did find crypt elongation in some proximal sections where no bioluminescence 
was detected (Fig. 28-29). Notably, we detected activated caspase-1 specifically in areas of biosensor 
activation (Fig. 30A-B). We also found increased expression of inflammatory cytokines/chemokines, 
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including IL-6, KC, IL-1β and TNF, in the colons isolated from DSS-treated mice relative to the untreated 
controls (Fig. 30C). Together, these data demonstrate that the IQAD biosensor is activated in inflamed 
regions of the colon in mice with colitis. 
 
 
Figure 28. Caspase-1 Biosensors are Activated in Inflamed Areas of the Colon During Colitis --Males. 
Representative images of biosensor signal in the colons of male mice treated with DSS for 5 d (DSS 01, DSS 02) 
and 7 d (DSS 54). Representative images of tissue sections acquired and histopathology assessed in the colons of 






Figure 29. Caspase-1 Biosensors are Activated in Inflamed Areas of the Colon During Colitis --Females. 
Representative images of biosensor signal in the colons of female mice treated with DSS for 7 d (DSS 08, 88, 14, 
64). Representative images of tissue sections acquired and histopathology assessed in the colons of mice with 
regions indicated with a “P” (proximal) or “D” (distal). Black arrows point to histopathological features of colitis 
including loss of crypts (08D, 88D), epithelial damage (08D), and inflammatory infiltration (88D, 14D), as well as 












Figure 30 - Biosensors are Activated in Regions of Caspase-1 Activation and Inflammatory 
Cytokine/Chemokine Production in the Colon. Tissue sections were isolated from regions of the colon where 
biosensor activation was detected (+) or control regions where no biosensor activation was detected (-) following 
DSS exposure (A). Tissues were homogenized and lysed for Western blot analysis of cleaved caspase-1 or β-actin 
(B). Heatmaps depict log2 fold change in cytokine/chemokine expression in the colons of DSS mice relative to the 
average of two control mice (C). 
 
 In addition to monitoring biosensor activation in the colons of mice with colitis, we wanted to 
determine if local inflammation in the colon affected inflammatory responses in other tissues. Day 5 and 
day 7 following DSS exposure, we detected increased bioluminescence in the brain, relative to untreated 
control animals (Fig. 31A-B). Biosensor activation persisted in DSS brain slices after one week in vitro, 
suggesting that the increased bioluminescence detected in the DSS brains is not due to an increase in 
luciferin distribution into the CNS resulting from increased blood-brain-barrier permeability (Fig. 31C). 
We hypothesized that the inflammatory response in the brain was the result of a systemic inflammatory 
response, however we did not detect inflammatory cytokines/chemokines in the serum until day 7, after 
we first detect biosensor activation (Fig. 31D). These data suggest that inflammasome activation occurs in 






Figure 31. Caspase-1 Biosensors are Activated in the Brain during Colitis. Representative images and 
quantification of biosensor activation in the brains on day 5 and day 7 following DSS exposure relative to control 
brains from mice given normal drinking water (A-B). Serum was collected from mice prior to sacrificing and 
imaging and harvested for CBA analysis (C). Control and DSS brains were sliced into 200μm sections using a 
microtome and cultured for one week on membrane inserts to derive organotypic brain slice cultures. Luciferase 
substrate was added to cultures and the brain slices were imaged after 1 week in vitro (D).   
 
Graft-Versus-Host Disease Model 
 
Recently, caspase-1 activation has been reported to occur in T cells during immune responses, 
including those occurring in models of autoimmune disease and inflammasome activation in T cells has 
been demonstrated to contribute to the production of inflammatory cytokines (13-15, 276, 277). Graft-
versus-host disease (GVHD) is a reaction that occurs following the transfer of donor immune cells (the 
graft) into an allogeneic host (278). Donor T cells recognize host alloantigens as foreign, resulting in the 
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activation of donor T cells and migration into host tissues including the skin, gastrointestinal tract and 
liver (278-280). We hypothesized that the biosensor would become activated in alloreactive donor T cells, 
and we could quantify bioluminescence in these cells and track their movement in the host over the 
course of disease. Furthermore, because the biosensor is only expressed in the donor cell population, we 
could specifically study inflammasome activation in donor cells during GVHD.  
To assess the IQAD biosensor in the context of GVHD, bone marrow cells and splenocytes were 
isolated from biosensor mice and transferred into irradiated WT C57Bl/6 mice (syngeneic transfer) or 
BALB/c mice (allogeneic transfer). As a control, bone marrow cells only were transferred into irradiated 
allogeneic recipients, as this is necessary to reconstitute the host hematopoietic system but does not cause 
GVHD in mice (281-283). At various time points post transfer, mice were imaged in vivo and 
bioluminescence was quantified. As expected, we found no biosensor activation in the syngeneic C57Bl/6 
mice or in the allogeneic BALB/c mice that received bone marrow cells only (Fig. 32A). However, robust 
biosensor signal was detected in vivo in BALB/c mice that received allogeneic bone marrow cells and 
splenocytes (Fig. 32A). Biosensor signal first appeared in an area near the site of the spleen and over 
time, the signal spread to the abdomen and ultimately to lymph nodes. On day 7, prior to euthanasia, mice 
were imaged in vivo, and then sacrificed and biosensor activation was quantified in tissues. We detected 
strong bioluminescence in the spleen and moderate signal in the intestines and mesenteric lymph nodes 
(Fig. 32B-C). Most of the luciferase signal in the intestinal tissues came from the mesenteric lymph 




Figure 32. Biosensors are Activated in Alloreactive Donor Cells during GVHD. Bone marrow cells (107) ± 5 
and 106 splenocytes isolated from biosensor mice were transferred into irradiated C57BL/6 syngeneic or BALB/c 
allogeneic recipient mice via i.v. injection into the tail vein. Representative IVIS images of mice at the indicated 
time points following syngeneic or allogeneic transfer of biosensor cells (A). Max radiance was quantified within 
the ROI for each mouse and graphed as fold max radiance relative to the max radiance detected on day 2, after 
transfer of biosensor cells, prior to disease development (A). On day 7, tissues were harvested and biosensor 
activation was measured ex vivo in the spleen, MLN, and intestines (B and C). Representative images from two 
GVHD mice, where the intestines and MLN are spread to better assess where the biosensor signal is coming from 
within the small intestine (D).  
 
By day 7, these mice exhibited increased clinical scores, as measured by decreased activity, 
hunched body posture and lack of grooming and had lost ~20-25% of their body weight, indicative of 






Figure 33. Mice Exhibit Clinical Measurements of GVHD. Clinical scores (A) and weight loss (B) were 
measured on day 7 in control and GVHD mice.  
 
We also detected increased levels of cytokines and chemokines in the serum of GVHD mice, 
including TNF and IL-6 (Fig 34). Although we are unable to determine if these cytokines/chemokines are 
donor or host derived, their presence in the serum is consistent with GVHD manifestation.  
 
Figure 34. Increased Inflammatory Cytokines in the Serum of GVHD mice. Serum was harvested from control 
and GVHD mice on day 7 and CBA analysis was performed to quantify the presence of the indicated cytokines and 
chemokines.  
 
To confirm the biosensor was activated in donor T cells, we performed the same experiment 
transferring BM cells and T cells isolated from caspase-1 biosensor mice. T cells were isolated by 
negative selection to make sure this population of cells remained untouched. Donor cells were transferred 
into syngeneic C57Bl/6 CD45.1 recipient or allogeneic BALB/c mice, and mice were sacrificed 7 days 
post-cell transfer and biosensor activation was measured in vivo and ex vivo. As before, we detected 
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biosensor activation in allogeneic recipient mice, specifically in the spleen, mesenteric lymph node and 
small intestines (Fig. 35A-C). We next isolated splenocytes and measured luciferase signal in vitro. We 
detected increased luciferase signal per cell in splenocytes isolated from allogeneic recipient mice 
compared to splenocytes isolated from the syngeneic control (Fig. 35D). Flow cytometric analysis of 
these splenocytes revealed increased CD8 to CD4 T cell ratio, a hallmark of GVHD (Fig. 35E). We also 
detected increased CD8 T cell activation in donor cells isolated from mice with GVHD (Fig. 35F). Since 
all mice received the same donor cell population, collectively these data suggest that the IQAD biosensor 









Figure 35. IQAD Biosensor is Activated in Donor T cells in Mice with GVHD. T cells were isolated from 
splenocytes from IQAD mice and purified by negative selection (>90% purity) and injected with BM cells into 
irradiated syngeneic CD45.1 C57Bl/6 or allogeneic BALB/c recipient mice and biosensor signal was measured in 
vivo 7 days later (A). Figure depicts one female (F0) and one male (M0) alongside a control (A). Tissues were 
harvested and bioluminescence was measured ex vivo in the spleens and intestines / mesenteric lymph nodes (B). 
Biosensor signal was quantified in the spleens (C). Spleens were collected from control and GVHD mice and 
splenocytes were isolated, lysed and biosensor signal was measured in 5 million cells (D). For flow cytometry 
analysis, splenocytes were stained with either anti-CD45.1 or anti-H-2Kb to gate on donor cells in the syngeneic or 
allogeneic recipients, respectively. Within donor populations, CD8+ and CD4+ populations were measured and 
CD8-to-CD4 ratios were measured (E). Within the CD8+ and CD4+ , CD44+ and CD25+ cells were quantified (F). 
 
Our in vitro data demonstrated that the IQAD biosensor could be turned on in response to both 
inflammatory and apoptotic stimuli. Our data above suggest that the IQAD biosensor is activated in 
alloreactive T cells, but another possible explanation could be that the biosensor is being turned on during 
T cell-activation induced cell death. To discriminate between these possibilities, we isolated splenocytes 
from mice with GVHD, gated on the donor cell population and then sorted the Annexin V positive and 
Annexin V negative cells. An equal number of sorted cells were lysed and luciferase activity was 
quantified. We did detect some biosensor activation in the Annexin V positive population of donor T 
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cells, which could be due to cell death during the isolation and sorting processes or this could indicate that 
the biosensor is active in dead/dying T cells in vivo (Fig. 36). Importantly, we found increased biosensor 
activation in the Annexin V negative population (Fig. 36), indicating that the IQAD biosensor is active in 
living alloreactive donor T cells. 
 
Figure 36. IQAD Biosensor is Activated in Alloreactive Donor T cells during GVHD. Spleens were harvested 
from GVHD mice, splenocytes were isolated and stained for host cells (H-2Kd) followed by Annexin V-FITC 
staining just prior to FACS. Cells were gated on donor cells (H-2kd-) and then sorted based on Annexin V staining. 
Cells were collected and the same number of cells were spun down and lysed for luciferase measurements. 
  
To determine if caspase-1 is active in alloreactive T cells, spleens were harvested from GVHD or 
control C57Bl/6 mice and the T cells were sorted for immunoblot. We used an antibody for caspase-1 that 
recognizes the p20 subunit and found increased expression of p33 (Fig. 37), the active species of caspase-
1 in cells (Fig. 7). These data indicate that caspase-1 is active in donor T cells during GVHD.  
 
Figure 37. Caspase-1 Activation in Donor T cells in GVHD Spleens. Spleens were harvested from control and 





EPS Treatment Reduces T cell Activation in GVHD Mice  
 
Exopolysaccharide (EPS) produced by the commensal bacterium, Bacillus subtilis, can protect 
mice from T cell-mediated inflammatory disease induced by the enteric pathogen Citrobacter rodentium 
and sepsis caused by infection of mice with the human pathogen Staphylococcus aureus (258, 284-286). 
EPS functions by inducing anti-inflammatory M2 macrophages in a TLR4-dependent manner, which 
ultimately inhibit T cell activation and proliferation (284). We hypothesized that EPS could protect mice 
from acute GVHD, and we could measure differences in biosensor activation between the protected EPS-
treated mice and mice with GVHD. Donor and recipient mice were injected with EPS or PBS prior to the 
induction of GVHD, and biosensor activation was measured over the course of disease. As before, we 
detected bioluminescence in the PBS-treated mice by day 5-7 post cell transfer (Fig. 38). However, no 
biosensor activation was detected in the EPS-treated mice on day 7, and two of the three mice continued 




Figure 38. Biosensor Activation is Attenuated in EPS-Treated Mice in vivo. On days -7, -5 and -3, biosensor 
donor mice and BALB/c recipient mice were injected with 300mg/kg of EPS in PBS or PBS only control. On Day 0, 
107 bone marrow cells + 5x106 splenocytes from biosensor mice were transferred into irradiated BALB/c mice via 
intravenous injection. As a control, bone marrow cells (107) only were transferred. Biosensor activation was 
monitored on the IVIS days 2, 5, 7 and 14 post-GVHD induction. Representative IVIS images of PBS- or EPS-
treated mice at the indicated time points following allogeneic transfer of biosensor cells (A). Max radiance was 
quantified within the ROI (red box) for each mouse and graphed as fold max radiance relative to the max radiance 
(B).  
 
Mice were sacrificed on day 7 after induction of GVHD, a time point where nearly all PBS mice 
reached criteria, and bioluminescence was quantified in the spleen and lymph nodes of PBS and EPS-
treated animals. We measured a marked reduction in biosensor activation in the spleens and intestines 
(that contained mesenteric lymph nodes) of EPS-treated mice relative to the PBS-treated group (Fig. 39A-
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C). We also assessed body weight loss during disease and found that by day 7, whereas 12 of 13 (92%) 
PBS-treated mice were moribund (i.e., lost more than 20% of body weight), only 6 of 15 (40%) EPS-
treated mice were moribund, indicating that 60% of the EPS-treated mice were protected (Fig. 39D). 
These data suggest that EPS can improve clinical manifestations of acute GVHD and this can be 
monitored by biosensor activation in live animals and tissues ex vivo.   
 
Figure 39. EPS-Treated Mice Exhibit Reduced Biosensor Signal in Tissues and Reduced Clinical Disease. PBS 
and EPS-tread mice were sacrificed on day 7, the spleen and small intestines with mesenteric lymph nodes were 
isolated and bioluminescence was quantified ex vivo (A-C). Weight loss was monitored over the course of disease 


















SUMMARY AND DISCUSSION 
 
In this study, we describe a bioluminescent sensor that quantitatively reports caspase-1 activation 
in cells and in living animals. We focused on caspase-1 since a diverse repertoire of PAMPs and DAMPS 
drive activation of a number of different inflammasomes, all of which culminate in the activation of 
caspase-1. The biosensor design was based on previously published circularly permuted luciferases that 
contain a protease recognition sequence between the two domains of the protein (230-233). We 
hypothesized that if a caspase-1 target sequence was placed into the luciferase construct, then we would 
detect luciferase signal whenever caspase-1 was active in a cell. We initially screened a number of 
caspase-1 target sequences and identified the strongest luciferase signal in cells expressing biosensors 
containing the IQAD or FLTD target sequences from procaspase-7 and gasdermin-D. Procaspase-7 is a 
well-established downstream target of caspase-1 (209, 238-240) and our data support this, as IQAD was 
cleaved in response to a variety of inflammatory stimuli in vitro and in vivo. Gasdermin-D is a well-
established target of caspase-1 (193, 209) and we detected similar luciferase activity with our GSDMD 
biosensor as with IQAD.     
While we call these ‘caspase-1 biosensors’ and can demonstrate that the biosensors are activated 
in response to a broad panel of inflammatory stimuli in vitro and inflammatory conditions in vivo where 
we detect active caspase-1, it is important to note that multiple caspases are capable of activating these 
biosensors. To date, no caspase-1 specific target sequence has been identified, making it impossible to 
design a biosensor that is specifically cleaved by caspase-1. The most well-established targets of caspase-
1 are proIL-1β, pro-IL-18, procaspase-7 and GSDMD, all of which are cleaved by other caspases and 
enzymes at the same amino acid sequence that is cleaved by caspase-1 (192, 214-218, 238, 287-290). 
Furthermore, there is such significant cross-talk between inflammatory and apoptotic pathways that it is 
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virtually impossible to separate these two pathways, particularly in the context of an inflammatory 
response in vivo.  
The concept of ‘inflammatory’ and ‘apoptotic’ caspases is outdated, as it is now well established 
that caspases integrate cell death and inflammatory pathways via a common axis (291, 292). Even if we 
did generate a biosensor that was somehow specifically cleaved by caspase-1, in addition to being 
activated during inflammation, this biosensor would also be turned on during apoptosis, since caspase-1 is 
activated in this cell death pathway (290, 293, 294). Despite the lack of specificity of our biosensors, we 
found that in vivo, the IQAD biosensor reliably directed us to locations of caspase-1 activation in tissues, 
while we did not detect biosensor signal in locations of apoptosis in vivo or ex vivo (i.e., the thymus). We 
suspect that the lack of biosensor activation during apoptosis is due to the fact that apoptotic cells are 
rapidly cleared by phagocytes in vivo (253, 254). Recently, caspase-8 has emerged as a driver of 
inflammation and numerous groups have demonstrated that functional inflammasomes can form with 
caspase-8 (125, 219-222). This could explain why the IQAD biosensor has performed so well in vitro and 
in vivo, since procaspase-7 is also cleaved by active caspase-8 (221, 238). So, while we were initially 
concerned that our putative biosensors could be turned on by other caspases, the fact that these biosensors 
are not specific for caspase-1 may make them more valuable for monitoring inflammatory responses.  
We did not detect biosensor activation in response to all stimuli tested. Some treatments tested 
may need to be optimized further, testing different concentrations, time points, drugs from different 
companies. However, we were able to detect increased markers of inflammation in response to some of 
these treatments, indicating that inflammatory cascades were activated. The finding that nigericin 
stimulates biosensor activation in differentiated THP-1s and MDMs but not mouse BMDMs was 
surprising, especially considering the high levels of caspase-1 activation detected by western blot and IL-
1β secretion from these cells. A possible explanation for this is a difference in caspase-1 target kinetics in 
BMDMs compared to THP-1 cells. We did detect more rapid biosensor activation in BMDMs, where 
bioluminescence peaked between 30 minutes and 1 hour, compared to THP-1 cells were bioluminescence 
accumulated over the course of 3 hours. Previous groups have proposed a 15 minute window for caspase-
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1 activation in nigericin-stimulated BMDMs, where peak caspase-1 activation occurs between 15 and 30 
minutes (49). The earliest time point for our luciferase measurements was 30 minutes. However, firefly 
luciferase is a relatively stable protein with a half-life of ~2h (295) and, once activated, should retain 
signal in living cells. Nonetheless, these data bring up an important caveat to our IQAD biosensor –it may 
not be activated every time caspase-1 is activated in cells.  
Surprisingly, we did not detect robust biosensor activation in cells transfected with LPS, relative 
to poly(I:C) and poly(dA:dT). Intracellular LPS activates the noncanonical inflammasome, leading to 
active caspase-1, we therefore suspected to detect strong bioluminescence. Instead, we detect ~2-6 fold 
increase in biosensor activation with all biosensors in human and mouse cells. We also detect some IL-1β 
production by ELISA, indicating that the inflammsome is active (data not shown). As mentioned earlier, 
we used serotype 055:B5 derived from E. coli, and serotype-dependent differences in noncanonical 
inflammasome activation have previously been reported (9). It will be interesting to perform further 
experiments using different LPS serotypes in cells expressing the IQAD or GSDMD biosensors. Since 
GSDMD is cleaved by caspases-4/5/11 as well as caspase-1, activation of this biosensor may be more 
robust compared to IQAD.  
Our ultimate goal was to use caspase-1 biosensors to monitor inflammatory responses in vivo. To 
this end, we chose a S. aureus infection model of systemic inflammation and colitis model of tissue-
specific inflammation to validate our biosensor in living animals and tissues ex vivo. We detected 
bioluminescence that accumulated over time in mice infected with S. aureus and in infected organs ex 
vivo. We also detected biosensor signal in the colons and brains of mice with colitis. One caveat to using 
transgenic mice expressing IQAD biosensors is the level of background bioluminescence. These mice can 
exhibit up to ~106 p/sec/cm2/sr biosensor signal under normal conditions, with the highest signal 
occurring at the site of injection (tail or peritoneal cavity). In our experiments, we overcame this by 
quantifying the fold change in biosensor activation relative to the signal measured on day 0. In our S. 
aureus infection model where we detected robust biosensor signal in infected animals, we were able to 
measure significant signal over background. However, the background signal can be problematic when 
92 
 
measuring small changes in bioluminescence in the abdomen area, as was the case with our colitis model. 
Additionally, detecting biosensor signal in vivo from certain tissues, like the kidneys, was difficult, 
because these organs are physically obstructed by other organs in the mouse. We have recently developed 
a system to surgically implant windows in various areas of the mouse (abdominal or cranial) which will 
help us monitor low levels of bioluminescence in live animals in tissues that are hard to measure, such as 
the brain.  
The high background biosensor activity was primarily detected in the abdomen. Some of this 
signal could be due to the food in the intestines. Alfalfa (chlorophyll) in mouse chow is very auto-
luminescent (296), and in fact, if we place normal mouse food in the IVIS machine, we detect significant 
signal from these food pellets (data not shown). In some experiments, such as the colitis model, we used 
Alfalfa-free chow to reduce this background signal in the colon. Even in mice fed this diet, the biosensor 
is still activated in the abdomen in vivo and intestine ex vivo. There may be some biological significance 
to low basal levels of caspase-1 activation in some tissues like the intestines, where cells are constantly 
being exposed to microbes. Low-grade inflammation may be important for maintaining immune 
homeostasis.   
Despite the background signal in vivo, the ability to detect distinct areas of caspase-1 activation 
within tissues proved to be advantageous in our colitis model. Biosensor signal reliably identified colonic 
regions of inflammation in a model of DSS. Notably, we detected active caspase-1 in tissues or regions of 
tissues that exhibited strong bioluminescence. These data highlight the potential of caspase-1 biosensor 
mice as guides to identifying locations in animals or within tissues where inflammatory responses are 
occurring.  
In our colitis model, biosensor signal was detected in distal sites from the diseased organ. We 
consistently measured higher signal in the brains isolated from mice exposed to DSS for 5-7 days. While 
there have been previous reports that colitis drives neuroinflammation (297), the mechanism for how this 
is happening remains elusive. DSS causes colitis by breaking down the epithelial barrier, which allows 
bacteria that normally reside in the lumen to activate immune cells in the lamina propria, driving an 
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inflammatory response. One hypothesis is that gut microbiota, a bacterial product or bacterial metabolite 
is driving inflammation in the brain. Alternatively, upon sensing inflammation in the colon, the vagus 
nerve may transmit this information to the brain, activating an inflammatory response in the CNS. A 
better understanding of how the brain senses peripheral dysbiosis and how tissue-specific inflammatory 
responses can drive changes in the brain is critical in numerous fields.   
We next wanted to evaluate the utility of our biosensor during graft-versus-host disease. We 
speculated that due to the aforementioned high background in the biosensor mice, it would be very 
difficult to detect subtle changes in biosensor activation in GVHD animals (the host). However, if we 
transferred hematopoietic cells expressing the biosensor into irradiated WT mice, then we would be able 
to specifically monitor biosensor activation in immune cell populations (the donor). Our data demonstrate 
that the IQAD biosensor was activated in alloreactive T cells in specific tissues, primarily the spleen, in 
irradiated allogeneic recipient mice. Donor cells were specifically activated in the context of GVHD, 
since little to no biosensor was detected in the allogeneic mice that received BM cells only or in the 
syngeneic mice that received the same population of BM cells and splenocytes. Biosensor signal was 
detected in Annexin V negative cells ex vivo. We also detected active caspase-1 (p33 species) in donor T 
cells isolated from GVHD mice, but not in T cells isolated from WT mice, indicating that caspase-1 is 
active in alloreactive, living T cells.  
Accumulating evidence has supported a role for NLRP3 inflammasome and caspase-1 activation 
and IL-1β production in T cells (13, 15) and, more generally, in autoimmune diseases (276, 277). Other 
groups have reported a T cell-intrinsic inflammasome that drives the production of IL-1β via NLRP3 and 
caspase-8 (14), and it is possible that caspase-8 is driving IQAD sensor activation in this model. 
Regardless of the caspase responsible for biosensor cleavage, the ability to monitor alloreactive T cell 
populations in vivo highlights the potential use of caspase-1 biosensors for monitoring T cell responses in 
the context of various autoimmune diseases.  
To determine if we could use IQAD biosensors to assess the severity of disease, we monitored 
biosensor activation during the course of acute GVHD in control mice and mice pre-treated with EPS. We 
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showed previously that EPS protects mice from several T-cell mediated diseases (258, 284, 286) and we 
hypothesized that EPS might also protect mice from acute GVHD. We found that pre-treatment with EPS 
prior to the induction of GVHD significantly improved clinical outcomes of the disease, as measured by 
weight loss and mortality. Importantly, we detected reduced biosensor activation in the EPS-treated mice 
compared to the control group. Because our data demonstrate that biosensor activation was due to the 
activation of alloreactive donor T cells, we can conclude that EPS affects (directly or indirectly) the 
activation of alloreactive donor T cells. Furthermore, biosensor activation allowed the severity of disease 
to be readily monitored and revealed the positive influence of EPS treatment in this setting. These data 
suggest that caspase-1 biosensors may be valuable for testing novel treatments in live animals.  
In conclusion, we developed a bioluminescent reporter that detects caspase-1 activation. This 
biosensor is activated in response to a variety of inflammatory stimuli and murine models of human 
disease. Inflammation is a dynamic process, and the ability to track and quantify the initiation and onset 
of inflammatory responses in individual animals over time has both experimental and economic value. 
Ultimately, we hope that this biosensor, when used concurrently with other conventional assays that 
measure inflammasome/caspase-1 activation will help to identify novel sites of inflammation in animals 
and tissues, which may facilitate the development and evaluation of future therapies for inflammatory 
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